glycopyrrolate has been researched along with Airflow Obstruction, Chronic in 254 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 187 (73.62) | 24.3611 |
| 2020's | 67 (26.38) | 2.80 |
| Authors | Studies |
|---|---|
| Kato, C; Nakamura, N; Sasajima, T; Yoshisue, H | 1 |
| Alessandri, M; Cresti, A; Lacerenza, LG; Lena, F; Montagnani, A; Perrella, A; Petrucci, E; Ricci, A; Rogliani, P; Scala, R; Scalese, M; Serafini, A; Sposato, B | 1 |
| Niu, X; Sanjar, S; Sharma, S; Tashkin, DP | 1 |
| Bougard, N; Louis, G; Louis, R; Pétré, B; Schleich, F | 1 |
| Bonhomme, O; Corhay, JL; Heinen, V; Louis, R; Nguyen, D; Van Cauwenberge, H | 1 |
| He, X; Liu, J; Wu, J | 1 |
| Chan, MC; Chen, NH; Cheng, SL; Hsieh, MJ; Hsu, WH; Kuo, PH; Lin, MS; Liu, CL; Liu, SF; Tao, CW; Tsai, YH; Wei, YF; Wu, YK; Yang, TM | 1 |
| Dorinsky, P; Jenkins, M; Krüll, M; Martinez, FJ; Patel, M; Rabe, KF; Singh, D | 1 |
| Enomoto, N; Fujisawa, T; Furuhashi, K; Hozumi, H; Ikegami, K; Inoue, Y; Inui, N; Kamiya, C; Kamiya, Y; Karayama, M; Katsumata, M; Maekawa, M; Nakamura, Y; Setou, M; Suda, T; Suzuki, Y; Tanaka, Y; Watanabe, H | 1 |
| Effendi, WI; Emoto, N; Hazama, D; Katsurada, N; Kobayashi, K; Nagano, T; Nishimura, Y; Ryanto, GRT; Suraya, R; Tachihara, M; Yamamoto, M | 1 |
| Agarwal, J; Compton, C; Czira, A; Dong, X; Duarte, M; Haeussler, K; Halpin, DMG; Ismaila, AS; Malmenäs, M; Nassim, M; Shen, Y; Tongbram, V; Vogelmeier, CF; Živković-Gojović, M | 1 |
| Arjomandi, M; Barjaktarevic, IZ; Brown, SA; Buhr, RG; Comellas, AP; Cooper, CB; Criner, GJ; Dransfield, MT; Drescher, F; Folz, RJ; Han, MK; Hansel, NN; Kalhan, R; Kaner, RJ; Kanner, RE; Krishnan, JA; Lazarus, SC; Maddipati, V; Martinez, FJ; Mathews, A; McEvoy, C; Meldrum, C; Nyunoya, T; Rogers, L; Sciurba, FC; Stringer, WW; Wang, D; Wendt, CH; White, E; Wise, RA; Wisniewski, SR; Woodruff, PG; Ye, W | 1 |
| Guo, M; Li, Z; Yu, C | 1 |
| Bouhaddi, M; Clairet, AL; Degano, B; Diallo, K; Elhage, S; Laurent, L; Puyraveau, M; Ritter, O; Soumagne, T | 1 |
| Aceituno, S; Baloira, A; Calvo, A; Garin, N; Martínez, A; Prades, M; Torres, C; Touron, C; Trigueros, JA | 1 |
| Brighton, N; de Nigris, E; Haughney, J; Holmgren, U; Treharne, C; Walker, A | 1 |
| Aurivillius, M; Bafadhel, M; Darken, P; Dorinsky, P; Jenkins, M; Martinez, FJ; Patel, M; Rabe, KF; Singh, D | 1 |
| Barjaktarevic, I; Hanania, NA; Mahler, DA; Make, B; Mintz, M; Skolnik, N; Yawn, B; Zeyzus-Johns, B | 1 |
| Figueira-Gonçalves, JM; Golpe, R; Guanche-Dorta, S; Ramallo-Fariña, Y; Wangüemert-Pérez, AL | 1 |
| Avorn, J; Feldman, WB; Gagne, JJ; Kesselheim, AS | 1 |
| Dell'Aniello, S; Ernst, P; Li, J; Suissa, S | 1 |
| Arslan, B; Çetin, GP; Yilmaz, İ | 1 |
| Gong, Y; Li, L; Lv, Y; Sui, Z; Zheng, Q | 1 |
| Banks, V; Castillo, C; Compton, C; Czira, A; Herth, FJF; Ismaila, AS; Quint, JK; Requena, G; Rothnie, KJ; Tritton, T; Wild, R; Wood, R; Yeap, J | 1 |
| Bates, JHT; Cortellini, M; De Backer, W; Galkin, D; Georges, G; Guasconi, A; Lavon, BR; Panni, I; Skloot, GS | 1 |
| Agatep, B; Edwards, D; Feigler, N; Lewing, B; Patel, S; Pollack, M; Portillo, E; Schinkel, J; Strange, C; Swisher, S; Tkacz, J; Touchette, DR | 1 |
| Singh, D | 2 |
| Calzetta, L; Cazzola, M; Facciolo, F; Matera, MG; Page, C; Rogliani, P | 1 |
| Darken, P; DeAngelis, K; Dorinsky, P; Dunn, LJ; Gillen, M; Kerwin, EM | 1 |
| Aurivillius, M; Ballal, S; Bourne, E; DeAngelis, K; Dorinsky, P; Ferguson, GT; Fukushima, Y; Hataji, O; Hayashi, N; Ichinose, M; Inoue, Y; Okada, H; Rabe, KF; Reisner, C; Takikawa, M | 1 |
| Ascuntar, C; Aviles, S; Benavides-Cordoba, V; Mosquera, R; Orozco, L; Rivera, J | 1 |
| Assam, PN; Chen, R; Huang, J; Maes, A; Martin, UJ; Mei, X; Qin, Z; Reisner, C; Siddiqui, S; Wang, HY; Zhao, L; Zhong, N | 1 |
| Arora, S; Jenkins, M; Lipworth, BJ; Martin, UJ; Martinez, FJ; Rabe, KF; Reisner, C | 1 |
| Alcazar, B; Barrecheguren, M; Kostikas, K; Mezzi, K; Miravitlles, M; Shen, S; Soler-Cataluña, JJ; Wedzicha, JA | 1 |
| Speer, G; Tamási, L | 1 |
| Assam, PN; Ballal, S; Bourne, E; Chen, R; DeAngelis, K; Dorinsky, P; He, H; Kang, J; Su, R; Wang, C; Yang, T; Zhao, L | 1 |
| Assam, PN; Jenkins, M; Lipworth, BJ; Wang, L; Xu, JF; Zheng, J | 1 |
| Banerji, D; Frent, SM; Gupta, P; Kostikas, K; Mackay, AJ; Olsson, P; Patalano, F; Pfister, P; Roche, N; Wedzicha, JA | 1 |
| Attri, S; Ballal, S; Darken, P; de Nigris, E; Ferguson, GT; Holmgren, U; Siddiqui, MK; Singh, B | 1 |
| Donohue, JF; Goodin, T; Ozol-Godfrey, A; Sanjar, S | 1 |
| Danyliv, A; Gutzwiller, FS; Lakhotia, B; Mahon, R; Nikolaev, I; Thokala, P | 1 |
| Goodin, T; Ohar, JA; Ozol-Godfrey, A; Sanjar, S | 1 |
| Collier, DJ; Feldman, GJ; Ferguson, GT; Jenkins, M; Lipworth, BJ; Martinez, FJ; O'Brien, G; Rabe, KF; Reisner, C; Sethi, S | 1 |
| Aurivillius, M; Ballal, S; Darken, P; Dorinsky, P; Ferguson, GT; Martinez, FJ; McLaren, J; Rabe, KF; Reisner, C; Singh, D; St Rose, E; Trivedi, R; Wang, C; Wedzicha, JA | 1 |
| Beier, J; Friedrich, FW; Plate, T | 1 |
| Caldwell-Tarr, A; Conto, RM; Dembek, C; Kerwin, EM; Paullin, M; Stephenson, JJ | 1 |
| Bourdin, A; Cazorla, O; Charriot, J; Grillet, PE; Le Souder, C; Rohou, J | 1 |
| Plunkett, C | 1 |
| Banerji, D; Frent, SM; Gupta, P; Kostikas, K; Mackay, AJ; Patalano, F; Pfister, PJ; Vogelmeier, CF; Wedzicha, JA | 1 |
| Carpaij, OA; Kerstjens, HAM; Niemeijer, A; Seigers, D; van Geffen, WH; Vonk, JM; Westbroek, LF | 1 |
| Gon, Y; Hayashi, N; Hirata, H; Maes, A; Martin, UJ; Nishi, K; Reisner, C; Sato, K; Siddiqui, S | 1 |
| Assam, PN; Dorinsky, P; Feng, C; Gillen, M; Huang, Y; Su, R | 1 |
| Calverley, P | 1 |
| Darken, P; Dorinsky, P; Martinez, FJ | 1 |
| Fernández-Villar, A; López-Campos, JL; Ruano-Ravina, A | 1 |
| Calzetta, L; Rogliani, P | 1 |
| Beaudot, C; De La Cruz, L; Edwards, M; Feldman, G; Georges, G; Kerwin, E; Pearle, J | 1 |
| Marth, K; Pohl, W; Renner, A | 1 |
| Bourdin, A; De Nigris, E; Ferguson, GT; Holmgren, U; Jenkins, M; Molinari, N; Ouwens, M; Siddiqui, MK; Singh, B | 1 |
| Cheng, SH; Hsu, YJ; Huang, YL; Lai, JH; Lin, CW; Liou, JT; Pan, HY; Tsai, CL; Wang, MT | 1 |
| Bartels, C; Jain, M; Tillmann, HC; Vaidya, S; Yu, J | 1 |
| Aritake, H; Gamo, S; Ichinose, M; Kazama, I; Murakami, K; Nara, M; Sugiura, H; Tamada, T | 1 |
| Elzinga, CRS; Han, B; Maarsingh, H; Meurs, H; Oldenburger, A; Schmidt, M; Sopi, RB; Timens, W; Zuidhof, AB | 1 |
| Aurivillius, M; De Backer, J; De Backer, W; Dorinsky, P; Jenkins, M; Trivedi, R; van den Berge, M; Van Holsbeke, C | 1 |
| Gallo, O; Mangia, PP; Pradelli, L; Ritrovato, D | 1 |
| Heo, YA | 1 |
| Nigro, SC; Sobieraj, DM | 1 |
| Abo, M; Hara, J; Kasahara, K; Kimura, H; Nishikawa, S; Ogawa, N; Ohkura, N; Sone, T; Tambo, Y; Tanaka, R; Watanabe, S | 1 |
| Corhay, JL | 1 |
| Blazhko, V; Cohuet, G; Corradi, M; Francisco, C; Montagna, I; Papi, A; Scuri, M; Singh, D; Vestbo, J; Vezzoli, S | 1 |
| Ficker, JH; Rabe, KF; Welte, T | 1 |
| Denenberg, M; Donohue, JF; Hanania, NA; Kerwin, EM; Maes, A; O'Donnell, DE; Orevillo, C; Quinn, D; Reisner, C; Siddiqui, S; Tashkin, DP | 1 |
| Rabe, KF | 1 |
| Banerji, D; Fogel, R; Fucile, S; Kostikas, K; Mezzi, K; Shen, S; Tsiligianni, I | 1 |
| Ciciliani, AM; Langguth, P; Wachtel, H | 1 |
| Aalamian-Mattheis, M; Castellani, W; Clemens, A; Gaga, M; Greulich, T; Kostikas, K; Lane, S; Marin, JM; Ninane, V; Nunez, X; Patalano, F; Vogelmeier, CF | 1 |
| Darken, P; Fabbri, LM; Ferguson, GT; Martin, UJ; Martinez, FJ; Orevillo, C; Reisner, C | 1 |
| Acerbi, D; Collarini, S; Mariotti, F; Muraro, A; Scuri, M; Singh, D; Vezzoli, S | 1 |
| Ellingson, S; Self, TH | 1 |
| Criner, GJ; Dhungana, S | 1 |
| Arora, S; Delacruz, L; Fakih, F; Feldman, G; Gottschlich, G; Koser, A; Krainson, J; Maes, A; Martin, U; Orevillo, C; Pudi, K; Reisner, C; Siddiqui, S; St Rose, E | 1 |
| Cazzola, M; Rogliani, P | 1 |
| Ferguson, GT; Goodin, T; Kerwin, E; Tosiello, R; Wheeler, A | 1 |
| Pong, CK | 1 |
| Buhl, R; Criée, CP; Kardos, P; Lossi, NS; Vogelmeier, CF; Worth, H | 1 |
| Ayers, T; Banerji, D; Ferguson, GT; Fogel, R; Goodin, T; Kerwin, E; Maitra, S; Sanjar, S; Sen, B; Yadao, A | 1 |
| Doty, A; Flynn, B; Lechuga-Ballesteros, D; Mack, P; Schroeder, J; Sommerville, M; Taylor, M; Vang, K | 1 |
| Corradi, M; Papi, A; Petruzzelli, S; Scuri, M; Singh, D; Spinola, M; Usmani, OS; Vestbo, J | 1 |
| Banerji, D; Fogel, R; Patalano, F | 1 |
| Physicians From Medical Centers In Poland, GO; Płusa, T | 1 |
| Bauer, A; Ferguson, GT; Goodin, T; Kerwin, E; Pham, S; Wheeler, A | 1 |
| Hida, N; Hizawa, N; Nakaizumi, T; Satoh, H; Terashima, H; Yamada, H | 1 |
| Cristiano, A; Radovanovic, D; Rizzi, M; Santus, P; Valenti, V | 1 |
| Donohue, JF; Goodin, T; Tosiello, R; Wheeler, A | 1 |
| Deas, SD; Huprikar, N | 1 |
| Bjermer, L; Costa-Scharplatz, M; Gutzwiller, FS; Keininger, DL; Lisspers, K; Mahon, R; Olsson, P; Roche, N; van Boven, JFM | 1 |
| Calzetta, L; Cavalli, F; Cazzola, M; Matera, MG; Ora, J; Puxeddu, E; Rogliani, P | 1 |
| Cohuet, G; Corradi, M; Fabbri, L; Guasconi, A; Montagna, I; Papi, A; Petruzzelli, S; Prunier, H; Roche, N; Scuri, M; Singh, D; Vestbo, J; Vezzoli, S | 1 |
| Kerwin, EM; Kollar, C; Reisner, C; Spangenthal, S; St Rose, E | 1 |
| Burke, C; Chow, WL; Guruprasad, B; Tee, A | 1 |
| Ferguson, GT; Maes, A; Martin, UJ; Reisner, C; Rodriguez-Roisin, R; Siddiqui, S | 1 |
| Aalamian-Mattheis, M; Clemens, A; Fogel, R; Kostikas, K; Nunez, X; Pagano, VA; Patalano, F | 1 |
| Ferguson, GT; Kerwin, E | 1 |
| Banerji, D; Chapman, KR; Fogel, R; Frent, SM; Goyal, P; Guerin, T; Hurst, JR; Kostikas, K; Larbig, M; Patalano, F; Pfister, P; Wedzicha, JA | 1 |
| Altman, P; Bader, G; D'Urzo, A; Goyal, P; Shen, S | 1 |
| Beeh, KM; Emirova, A; Nandeuil, MA; Prunier, H; Santoro, D | 1 |
| Iwakura, M; Satake, M; Sato, S; Shioya, T; Takahashi, H; Terui, Y; Uemura, S | 1 |
| Anzueto, AR; Banerji, D; Fogel, R; Kostikas, K; Larbig, M; Mezzi, K; Patalano, F; Shen, S; Wedzicha, JA | 1 |
| Gross, NJ; Tashkin, DP | 1 |
| Darken, P; Kerwin, EM; Pearle, J; Reisner, C; Rose, ES | 1 |
| Banerji, D; Chapman, KR; Fogel, R; Frent, SM; Gutzwiller, FS; Kostikas, K; Larbig, M; Mackay, A; Patalano, F; Shen, S; Wedzicha, JA | 1 |
| Ashmawi, S; Backer, A; Diaz, DV; Frith, PA; Gurgun, A; Hamann, AM; Hristoskova, S; Kostikas, K; Krishnamurthy, S; Olsson, P; Pilipovic, V | 1 |
| Blasi, F; Mantero, M; Radovanovic, D; Santus, P | 1 |
| Pleasants, RA | 1 |
| Clukers, J; De Backer, J; De Backer, W; Hajian, B; Jenkins, M; Martin, UJ; Reisner, C; Siddiqui, S; Van Holsbeke, C; Verlinden, I; Vos, W | 1 |
| Bafadhel, M | 1 |
| Fakih, F; Feldman, G; Mack, P; Maes, A; Pudi, K; Reisner, C; Siddiqui, S; St Rose, E | 1 |
| Donohue, JF; Ferguson, GT; Ganapathy, V; Kerwin, EM; Ozol-Godfrey, A; Rajagopalan, K | 1 |
| Kuna, P; Kupczyk, M | 1 |
| Kasak, V; Klimes, J; Skoupa, J; Valena, T | 1 |
| Fogel, R; Fucile, S; Goyal, P; Jenkins, C; Kostikas, K; Mezzi, K; Shen, S; Singh, D; Tsiligianni, I; Wedzicha, JA | 1 |
| Bentivenga, C; Berardi, E; Borghi, C; Bui, V; Cicero, AF; Cosentino, ER; Esposti, DD; Landolfo, M; Miceli, R; Spinardi, L | 1 |
| Lad, R; Rhee, CK; Yoshisue, H | 1 |
| Corradi, M; Fabbri, LM; Georges, G; Guasconi, A; Papi, A; Petruzzelli, S; Singh, D; Vezzoli, S | 1 |
| Abels, C; Chabicovsky, M; Kilic, A; Masur, C; Soeberdt, M; Winkler, S | 1 |
| Dorman, J; Kelly, K; Lacey, S; McGrath, K; Molony, D; O'Doherty, B; Schmid, S; Sullivan, S; Whelan, S | 1 |
| Douglas, M | 1 |
| Bourdin, A; Deslee, G; Feldman, GJ; Ferguson, GT; Fjällbrant, H; Jenkins, MA; Maltais, F; Martin, UJ; Siwek-Posłuszna, A | 1 |
| Bowling, A; Goodin, T; Ozol-Godfrey, A; Price, B; Sanjar, S; Sharma, S; Tashkin, DP | 1 |
| DeAngelis, K; Dorinsky, P; Ferguson, GT; Kerwin, EM; Mo, M | 1 |
| Bartels, C; Kaiser, G; Looby, M; Sechaud, R | 1 |
| Carter, NJ | 1 |
| Wise, J | 1 |
| Alagappan, VK; Banerji, D; Chapman, KR; Chen, H; Dahl, R; Kho, P; Mehta, R; Rudolf, M | 1 |
| Schachter, EN | 1 |
| D'Andrea, P; Molimard, M | 1 |
| Ulrik, CS | 6 |
| Thompson, H | 1 |
| Greening, A; Huisman, E; Karabis, A; Lindner, L; Mocarski, M | 1 |
| Baldwin, M; Buckley, F; Capkun-Niggli, G; Cope, S; Donohue, JF; Ellis, A; Jansen, JP; Jones, P; Kraemer, M | 1 |
| Hiratsuka, M; Kozawa, M; Nakanishi, M; Yoshisue, H | 1 |
| Alagappan, VK; Banerji, D; Chen, H; Dahl, R; Jadayel, D | 1 |
| Alagappan, VK; Banerji, D; Chen, H; D'Urzo, A; Decramer, M; Gallagher, N; Kulich, K; Mahler, DA; White, T; Worth, H | 1 |
| Beeh, KM | 1 |
| Antoniu, S; Râjnoveanu, RM; Ulmeanu, R | 1 |
| Tashkin, DP | 1 |
| Alagappan, VK; Banerji, D; Bateman, ED; Chen, H; D'Andrea, P; Pallante, J; Vogelmeier, CF | 1 |
| Chen, XP; Dong, XW; Jia, YL; Jin, F; Liu, YN; Shen, HJ; Shen, LL; Sun, Y; Wen, C; Xie, QM | 1 |
| Han, MK | 1 |
| Arrasate, C; Banerji, D; Chen, H; D'Andrea, P; Decramer, M; Ficker, JH; Niewoehner, DE; Sandström, T; Taylor, AF; Wedzicha, JA | 2 |
| Yaqub, F | 1 |
| Van Meerhaeghe, A; Vanhaeverbeek, M | 1 |
| Bateman, ED; Beeh, KM; Beier, J; Chapman, KR; Chen, H; D'Andrea, P; D'Urzo, A; Henley, M; Nutbrown, R; Overend, T | 1 |
| Peeters, S; Warnez, M | 1 |
| Banerji, D; Beeh, KM; Beier, J; D'Andrea, P; Henley, M; Jadayel, D; Korn, S | 1 |
| Plaza, V; Rodrigo, GJ | 1 |
| Aumann, J; Chen, H; Goyal, P; Henley, M; McBryan, D; Vincken, W | 1 |
| Frampton, JE | 1 |
| Banerji, D; Bateman, ED; Mahler, DA; Patalano, F; Vogelmeier, CF; Wedzicha, JA | 1 |
| Darken, P; Fernandez, C; Fischer, T; Fogarty, C; Golden, M; Orevillo, C; Reisner, C; Rennard, S; Rose, ES; Tardie, G | 1 |
| Banerji, D; Buhl, R; Chen, H; D'Andrea, P; Dahl, R; Fogel, R; Schubert-Tennigkeit, A; Wedzicha, JA | 1 |
| Calzetta, L; Cazzola, M; Facciolo, F; Matera, MG; Rogliani, P; Segreti, A | 1 |
| Barnes, PJ; Jones, CR; Leaker, BR; Singh, D; Tutuncu, A | 1 |
| Asukai, Y; Costa-Scharplatz, M; Dimova, M; Keininger, D; Mezzi, K; Price, D; Ställberg, B | 1 |
| Cazzola, M; Matera, MG; Rogliani, P | 2 |
| Maselli, R; Matera, MG; Pelaia, G | 1 |
| Incorvaia, C; Riario-Sforza, E; Riario-Sforza, GG; Ridolo, E | 2 |
| Buhl, R; Criée, CP; Kardos, P; Vogelmeier, C; Worth, H | 1 |
| Bai, L; D'Andrea, P; Firth, R; Huang, Y; Humphries, M; Kho, P; Li, L; Sun, T; Wang, C; Wang, Q | 1 |
| Babu, KS; Morjaria, JB; Prakash, A | 1 |
| Buhl, R; Foerster, K; Gessner, C; Hiltl, S; Korn, S; Schuermann, W; Sieder, C | 1 |
| Baroni, M; Incorvaia, C; Montagni, M; Riario-Sforza, GG; Ridolo, E | 1 |
| Kozielski, J | 1 |
| Jones, PW | 1 |
| Bremner, P; Chang, CL; Day, P; Frenzel, C; Frith, PA; Kurstjens, N; Ratnavadivel, R; Thompson, PJ | 1 |
| Calzetta, L; Cazzola, M; Lipsi, R; Matera, MG; Ora, J; Rogliani, P; Segreti, A | 1 |
| Horita, N; Kaneko, T | 1 |
| Banerji, D; Humphries, M; Patalano, F; Thach, C; Wang, C; Wang, L; Zhang, N; Zhong, N; Zhou, X | 1 |
| Lipworth, B | 1 |
| Ayers, T; Banerji, D; FowlerTaylor, A; Kerwin, E; Lloyd, M; Mahler, DA; Maitra, S; Patalano, F; Thach, C | 1 |
| Nagy, LB | 1 |
| Cazzola, M; Poletti, V; Rossi, A; Zanardi, E | 1 |
| Hubert, M | 2 |
| Altman, P; Chapman, KR; D'Andrea, P; D'Urzo, AD; Decramer, M; DiGiovanni, R; Goyal, P; Hu, H; Kerwin, EM | 1 |
| Asukai, Y; Costa-Scharplatz, M; Goyal, P; Gruenberger, JB; Price, D; Ställberg, B | 1 |
| Cockle, SM; Huisman, EL; Ismaila, AS; Karabis, A; Punekar, YS | 1 |
| Lindberg, M | 1 |
| Donohue, JF | 2 |
| Centanni, S; Di Marco, F; Raccanelli, R; Radovanovic, D; Santus, P; Valenti, V | 1 |
| Disse, B; Hallmann, C; Metzdorf, N | 1 |
| Huisman, EL; Ismaila, AS; Karabis, A; Punekar, YS | 1 |
| Buck, H; Down, G; O'Connor, G; Ravi, A; Reid, F; Singh, D | 1 |
| Einecke, D | 3 |
| Bartels, C; Bieth, B; Demin, I; Gautier, A; Graham, G; Sechaud, R; Tillmann, HC | 1 |
| Anzueto, A; Halpin, DM; Metzdorf, N; Pieper, MP; Richard, F; Vogelmeier, C | 1 |
| Bonnet-Gonod, F; Cohuet, G; Hoffmann, M; Muraro, A; Petruzzelli, S; Schröder-Babo, W; Siergiejko, Z; Singh, D | 1 |
| Ayers, RT; Banerji, D; Chapman, KR; Fogel, R; Patalano, F; Roche, N; Thach, C; Vestbo, J; Vogelmeier, CF; Wedzicha, JA | 1 |
| Banerjee, R; D'Andrea, P; Eckert, JH; Gifford, AH; Jessop, N; Mahler, DA; Mota, F; Satti, A | 1 |
| Kuwahira, I | 1 |
| Al-Majed, NS; Chiu, MH; Pollmann, D; Sandhu, RK; Stubbins, R | 1 |
| Baier, M; Kirsten, A; Mailänder, C; Watz, H | 1 |
| D'Andrea, P; Eckert, JH; Feldman, G; Henley, M; LaForce, C; Patalano, F; Spangenthal, S | 1 |
| Fernández-Villar, A; Leiro-Fernández, V; Priegue Carrera, A | 1 |
| Aalamian-Mattheis, M; Beeh, KM; Casamor, R; Castellani, W; Clemens, A; Gunstone, A; Kostikas, K; Marin, JM; Saralaya, D; Schaper, L | 1 |
| Carrasco, J; Chehab, S; Gruenberger, JB; Keininger, DL; Molimard, M; Pitotti, C; Price, D; Reza Maleki-Yazdi, M; Sauvage, E | 1 |
| Aliberti, S; Di Marco, F; Mantero, M; Radovanovic, D; Santus, P; Sferrazza Papa, GF; Valenti, V | 1 |
| Banerji, D; Vogelmeier, CF; Wedzicha, JA | 1 |
| Suissa, S | 1 |
| Franssen, FM; Vanfleteren, LE; Wouters, EF | 1 |
| Contoli, M; Morelli, P; Papi, A | 1 |
| Darken, P; Dwivedi, S; Fabbri, LM; Ferguson, GT; Fischer, T; Golden, M; Kerwin, EM; Orevillo, C; Pearle, J; Reisner, C; Rodriguez-Roisin, R; Sethi, S; Spangenthal, S; St Rose, E | 1 |
| Ito, YM; Kanda, R; Konno, S; Makita, H; Nakano, Y; Nishimura, M; Ogawa, E; Seto, R; Shimizu, K; Suzuki, M | 1 |
| Darken, P; Denenberg, M; Donohue, JF; Fischer, T; Fogarty, C; Golden, M; Gotfried, M; Gottschlich, G; Martinez, FJ; Orevillo, C; Reisner, C; Rodriguez-Roisin, R; St Rose, E; Strom, S; Tashkin, DP | 1 |
| Arora, S; Darken, P; Fabbri, LM; Feldman, GJ; Ferguson, GT; Fischer, T; Golden, M; Gottschlich, GM; Maes, A; Martinez, FJ; Orevillo, C; Rabe, KF; Reisner, C; Rennard, S; Rodriguez-Roisin, R; Sethi, S; Siddiqui, S; Siler, TM; Spangenthal, S | 1 |
| Baier, M; Kirsten, AM; Mailänder, C; May, C; Watz, H | 1 |
| Bader, G; Banerji, D; Fogel, R; Humphries, MJ; Mezzi, K; Patalano, F; Vogelmeier, C; Zhong, N | 1 |
| Darken, P; Donohue, JF; Dwivedi, S; Fabbri, LM; Ferguson, GT; Fischer, T; Fogarty, C; Golden, M; Kerwin, EM; Martinez, FJ; Orevillo, C; Rabe, KF; Reisner, C; Spangenthal, S; St Rose, E; Strom, S | 1 |
| Azzola, A; Brutsche, M; Clemens, A; Domenighetti, G; Fitting, JW; Frey, JG; Geiser, T; Kostikas, K; Salomon, J; Schmidt, U; Sigrist, T; Stolz, D; Turk, AJ; Wild, C | 1 |
| Hwang, YI; Jung, JY; Jung, KS; Kim, S; Kim, TH; Lee, JH; Lee, SW; Park, HY; Park, JW; Rhee, CK | 1 |
| Kadoya, K; Kaga, N; Liu, X; Nagahama, KY; Namba, Y; Orimo, A; Taka, H; Takahashi, K; Togo, S; Tulafu, M | 1 |
| Cheung, D; Galdiz, JB; Güçlü, SZ; Henley, M; Mizutani, G; Overend, T; Spangenthal, S; Verkindre, C; Vogelmeier, C; Zeldin, RK | 1 |
| Dolker, M; Flémale, A; Fukuchi, Y; Overend, T; Prasad, N; Takeda, A; Verkindre, C | 1 |
| Buhl, R; Dolker, M; Jones, F; Laforce, C; Martin, C; Overend, T; van Noord, JA | 1 |
| Di Scala, L; Drollmann, A; Fogarty, C; Hattersley, H | 1 |
| Dolker, M; Fabbri, LM; Horton, R; Martin, C; Overend, T; Van de Maele, B | 1 |
| Koshika, T; Niiya, R; Ogoda, M; Yamada, S | 1 |
| Banerji, D; Vogelmeier, C | 1 |
| Banerji, D; D'Urzo, A; Ferguson, GT; Hirata, K; Horton, R; Lu, Y; Martin, C; Overend, T; van Noord, JA | 1 |
| Drollmann, A; Kaiser, G; Motte, Sde L; Renard, D; Sechaud, R; Zhang-Auberson, L | 1 |
| Beeh, KM; Di Scala, L; Drollmann, A; Singh, D | 1 |
| Alagappan, VK; Banerji, D; Gallagher, N; Hébert, J; Kerwin, E; Lu, Y; Martin, C; Overend, T | 1 |
| Banerji, D; Buhl, R | 1 |
| Alagappan, V; Arievich, H; Banerji, D; Gibbs, M; Looby, M; Overend, T; Renard, D | 1 |
61 review(s) available for glycopyrrolate and Airflow Obstruction, Chronic
| Article | Year |
|---|---|
Impact of baseline clinical features on outcomes of nebulized glycopyrrolate therapy in COPD.
Topics: Administration, Inhalation; Bronchodilator Agents; Glycopyrrolate; Humans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Treatment Outcome | 2021 |
Economic Evaluation of Triple Therapy with Budesonide/Glycopyrrolate/Formoterol Fumarate for the Treatment of Moderate to Very Severe Chronic Obstructive Pulmonary Disease in China Using a Semi-Markov Model.
Topics: Administration, Inhalation; Bronchodilator Agents; Budesonide; Clinical Studies as Topic; Cost-Benefit Analysis; Drug Combinations; Formoterol Fumarate; Fumarates; Glycopyrrolate; Humans; Metered Dose Inhalers; Pulmonary Disease, Chronic Obstructive | 2022 |
Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Drug Combinations; Dyspnea; Forced Expiratory Volume; Glycopyrrolate; Humans; Muscarinic Antagonists; Network Meta-Analysis; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Salmeterol Xinafoate; Tiotropium Bromide; Treatment Outcome | 2022 |
The Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol in the Treatment of COPD in the Elderly.
Topics: Aged; Bronchodilator Agents; Budesonide; Drug Combinations; Formoterol Fumarate; Glycopyrrolate; Humans; Pulmonary Disease, Chronic Obstructive | 2022 |
Reducing the Risk of Mortality in Chronic Obstructive Pulmonary Disease With Pharmacotherapy: A Narrative Review.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Bronchodilator Agents; COVID-19; Drug Therapy, Combination; Formoterol Fumarate; Glycopyrrolate; Humans; Pulmonary Disease, Chronic Obstructive | 2023 |
The Role of Long-Acting Antimuscarinic Agents in the Treatment of Asthma.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Asthma; Bronchodilator Agents; Cholinergic Antagonists; Glycopyrrolate; Humans; Inflammation; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Tiotropium Bromide | 2023 |
LABA/LAMA versus LABA/ICS fixed-dose combinations in the prevention of COPD exacerbations: a modeling analysis of literature aggregate data.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Drug Combinations; Fluticasone; Formoterol Fumarate; Glycopyrrolate; Humans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive | 2023 |
Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Aged; Bayes Theorem; Bronchodilator Agents; Budesonide; Drug Combinations; Dyspnea; Female; Forced Expiratory Volume; Formoterol Fumarate; Fumarates; Glycopyrrolate; Humans; Male; Metered Dose Inhalers; Middle Aged; Muscarinic Agonists; Muscarinic Antagonists; Network Meta-Analysis; Pulmonary Disease, Chronic Obstructive; Respiratory Function Tests; Treatment Outcome | 2020 |
Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies.
Topics: Administration, Inhalation; Adult; Aged; Aged, 80 and over; Bronchodilator Agents; Clinical Trials, Phase III as Topic; Double-Blind Method; Drug Therapy, Combination; Female; Formoterol Fumarate; Glycopyrrolate; Humans; Lung; Male; Metered Dose Inhalers; Middle Aged; Multicenter Studies as Topic; Pulmonary Disease, Chronic Obstructive; Randomized Controlled Trials as Topic; Respiratory Function Tests; Severity of Illness Index | 2020 |
Glycopyrrolate and formoterol fumarate for the treatment of COPD.
Topics: Administration, Inhalation; Bronchodilator Agents; Formoterol Fumarate; Glycopyrrolate; Humans; Pulmonary Disease, Chronic Obstructive | 2021 |
Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol Fumarate versus Other Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Bayes Theorem; Bronchodilator Agents; Budesonide; Drug Combinations; Formoterol Fumarate; Fumarates; Glycopyrrolate; Humans; Muscarinic Antagonists; Network Meta-Analysis; Pulmonary Disease, Chronic Obstructive; Quality of Life | 2021 |
Population Pharmacokinetic Analysis of Indacaterol/Glycopyrronium/Mometasone Furoate After Administration of Combination Therapies Using the Breezhaler
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Anti-Asthmatic Agents; Asthma; Child; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Combinations; Female; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Models, Biological; Mometasone Furoate; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinolones; Randomized Controlled Trials as Topic; Young Adult | 2021 |
Budesonide/Glycopyrronium/Formoterol: A Review in COPD.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Budesonide; Drug Combinations; Formoterol Fumarate; Glucocorticoids; Glycopyrrolate; Humans; Metered Dose Inhalers; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive | 2021 |
Budesonide/Glycopyrrolate/Formoterol Fumarate Co-suspension Metered Dose Inhaler: A Triple Therapy for the Treatment of Chronic Obstructive Pulmonary Disease.
Topics: Bronchodilator Agents; Budesonide; Double-Blind Method; Drug Combinations; Formoterol Fumarate; Fumarates; Glycopyrrolate; Humans; Metered Dose Inhalers; Pulmonary Disease, Chronic Obstructive | 2022 |
Role of dual bronchodilators in COPD: A review of the current evidence for indacaterol/glycopyrronium.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Animals; Bronchodilator Agents; Drug Combinations; Glucocorticoids; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Severity of Illness Index | 2017 |
New Treatment Option for Chronic Obstructive Pulmonary Disease: Two Long-Acting Bronchodilators in a Single Metered-Dose Inhaler.
Topics: Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Delayed-Action Preparations; Drug Combinations; Formoterol Fumarate; Glycopyrrolate; Humans; Muscarinic Antagonists; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Treatment Outcome | 2017 |
Spotlight on glycopyrronium/formoterol fumarate inhalation aerosol in the management of COPD: design, development, and place in therapy.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Disease Progression; Drug Combinations; Forced Expiratory Volume; Formoterol Fumarate; Glycopyrrolate; Humans; Lung; Metered Dose Inhalers; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Time Factors; Treatment Outcome | 2017 |
Comparative effectiveness of indacaterol/glycopyrronium in the treatment of chronic obstructive pulmonary disease.
Topics: Adrenal Cortex Hormones; Bronchodilator Agents; Comparative Effectiveness Research; Drug Combinations; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Observational Studies as Topic; Pulmonary Disease, Chronic Obstructive; Quinolones; Randomized Controlled Trials as Topic; Treatment Outcome | 2017 |
Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Beclomethasone; Bronchodilator Agents; Disease Progression; Drug Combinations; Evidence-Based Medicine; Exercise Tolerance; Forced Expiratory Volume; Formoterol Fumarate; Glucocorticoids; Glycopyrrolate; Humans; Lung; Muscarinic Antagonists; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Recovery of Function; Risk Factors; Time Factors; Treatment Outcome | 2017 |
Indacaterol/glycopyrronium: a dual bronchodilator for COPD.
Topics: Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Drug Approval; Drug Combinations; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Treatment Outcome | 2018 |
Role of nebulized glycopyrrolate in the treatment of chronic obstructive pulmonary disease.
Topics: Administration, Inhalation; Animals; Glycopyrrolate; Humans; Molecular Structure; Pulmonary Disease, Chronic Obstructive | 2017 |
Dual bronchodilator therapy for chronic obstructive pulmonary disease: evidence for the efficacy and Safety of fixed dose combination treatments in the setting of recent guideline updates.
Topics: Administration, Inhalation; Benzoxazines; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Delayed-Action Preparations; Drug Combinations; Formoterol Fumarate; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Practice Guidelines as Topic; Pulmonary Disease, Chronic Obstructive; Quinolones; Quinuclidines; Tiotropium Bromide; Tropanes | 2018 |
An overview of glycopyrrolate/eFlow® CS in COPD.
Topics: Clinical Trials as Topic; Glycopyrrolate; Humans; Muscarinic Antagonists; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive | 2018 |
Improvement of physical activity in chronic obstructive pulmonary disease by pulmonary rehabilitation and pharmacological treatment.
Topics: Adrenergic beta-2 Receptor Agonists; Behavior; Counseling; Delayed-Action Preparations; Drug Therapy, Combination; Energy Metabolism; Exercise; Formoterol Fumarate; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolones; Self Efficacy; Terbutaline; Treatment Outcome; Tropanes | 2018 |
Inhaled glycopyrrolate for the treatment of chronic obstructive pulmonary disease.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Europe; Glycopyrrolate; Humans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quality of Life; Receptor, Muscarinic M2; Receptor, Muscarinic M3; Treatment Outcome | 2018 |
Management of severe COPD exacerbations: focus on beclomethasone dipropionate/formoterol/glycopyrronium bromide.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Beclomethasone; Bronchodilator Agents; Disease Progression; Drug Therapy, Combination; Formoterol Fumarate; Glucocorticoids; Glycopyrrolate; Humans; Pulmonary Disease, Chronic Obstructive; Quality of Life; Randomized Controlled Trials as Topic | 2018 |
Glycopyrrolate/eFlow CS: The First Nebulized Long-Acting Muscarinic Antagonist Approved to Treat Chronic Obstructive Pulmonary Disease.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Drug Delivery Systems; Female; Glycopyrrolate; Humans; Male; Muscarinic Antagonists; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Treatment Outcome | 2019 |
Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide as a combination therapy for chronic obstructive pulmonary disease.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Beclomethasone; Bronchodilator Agents; Cholinergic Antagonists; Drug Therapy, Combination; Formoterol Fumarate; Glucocorticoids; Glycopyrrolate; Humans; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive | 2019 |
Fixed-Dose Combinations of Long-Acting Bronchodilators for the Management of COPD: Global and Asian Perspectives.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Asian People; Benzoxazines; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Drug Combinations; Formoterol Fumarate; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Quinuclidines; Tiotropium Bromide; Treatment Outcome; Tropanes | 2019 |
Pharmacology, toxicology and clinical safety of glycopyrrolate.
Topics: Administration, Inhalation; Administration, Oral; Administration, Topical; Animals; Carcinogenicity Tests; Cholinergic Antagonists; Female; Glycopyrrolate; Humans; Hyperhidrosis; Male; Molecular Structure; Mutagenicity Tests; Pulmonary Disease, Chronic Obstructive; Reproduction | 2019 |
Inhaled glycopyrronium bromide: a review of its use in patients with moderate to severe chronic obstructive pulmonary disease.
Topics: Administration, Inhalation; Drug Interactions; Glycopyrrolate; Humans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive | 2013 |
▾Glycopyrronium for COPD.
Topics: Administration, Inhalation; Bronchodilator Agents; Delayed-Action Preparations; Glycopyrrolate; Humans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive | 2013 |
Indacaterol/glycopyrronium bromide fixed-dose combination for the treatment of COPD.
Topics: Adrenergic beta-2 Receptor Agonists; Drug Combinations; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones | 2013 |
Once-daily glycopyrronium via the Breezhaler® device for the treatment of COPD: pharmacological and clinical profile.
Topics: Administration, Inhalation; Animals; Clinical Trials as Topic; Drug Administration Schedule; Dry Powder Inhalers; Glycopyrrolate; Humans; Molecular Structure; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Treatment Outcome | 2013 |
[Glycopyrronium bromide is a long-acting inhaled anticholinergic in the treatment of severe COPD].
Topics: Administration, Inhalation; Bronchodilator Agents; Delayed-Action Preparations; Forced Expiratory Volume; Glycopyrrolate; Humans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Treatment Outcome | 2013 |
Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysis.
Topics: Bayes Theorem; Bronchodilator Agents; Forced Expiratory Volume; Glycopyrrolate; Humans; Lung; Muscarinic Antagonists; Odds Ratio; Pulmonary Disease, Chronic Obstructive; Recovery of Function; Scopolamine Derivatives; Severity of Illness Index; Tiotropium Bromide; Treatment Outcome; Tropanes | 2013 |
Comparative efficacy of long-acting bronchodilators for COPD: a network meta-analysis.
Topics: Albuterol; Bayes Theorem; Bronchodilator Agents; Delayed-Action Preparations; Dose-Response Relationship, Drug; Ethanolamines; Formoterol Fumarate; Glycopyrrolate; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones; Randomized Controlled Trials as Topic; Salmeterol Xinafoate; Scopolamine Derivatives; Severity of Illness Index; Tiotropium Bromide; Treatment Outcome | 2013 |
[New therapeutic choice for COPD: glycopyrronium bromide, a long-acting muscarinic antagonist].
Topics: Administration, Inhalation; Animals; Clinical Trials as Topic; Delayed-Action Preparations; Glycopyrrolate; Humans; Muscarinic Antagonists; Protein Binding; Pulmonary Disease, Chronic Obstructive; Receptors, Muscarinic | 2013 |
Efficacy and safety of a fixed-dose combination of indacaterol and Glycopyrronium for the treatment of COPD: a systematic review.
Topics: Dose-Response Relationship, Drug; Drug Therapy, Combination; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Practice Guidelines as Topic; Pulmonary Disease, Chronic Obstructive; Quinolones; Randomized Controlled Trials as Topic; Treatment Outcome | 2014 |
QVA149 (indacaterol/glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary disease.
Topics: Administration, Inhalation; Bronchodilator Agents; Clinical Trials, Phase III as Topic; Drug Combinations; Glycopyrrolate; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones; Respiratory Function Tests; Severity of Illness Index; Treatment Outcome | 2014 |
Glycopyrronium for inhalation. COPD: another antimuscarinic with cardiac adverse effects that require monitoring.
Topics: Administration, Inhalation; Clinical Trials as Topic; Drug Interactions; Electrocardiography; Glycopyrrolate; Heart Diseases; Humans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive | 2014 |
Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Drug Administration Schedule; Drug Combinations; Glycopyrrolate; Humans; Indans; Lung; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Randomized Controlled Trials as Topic; Recovery of Function; Time Factors; Treatment Outcome | 2014 |
Recent advances in COPD disease management with fixed-dose long-acting combination therapies.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Albuterol; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Disease Management; Disease Progression; Drug Combinations; Ethanolamines; Formoterol Fumarate; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Quinuclidines; Salmeterol Xinafoate; Scopolamine Derivatives; Tiotropium Bromide; Treatment Outcome | 2014 |
[The combination of indacaterol and glycopyrronium has effects on symptoms, lung function, and rate of exacerbations in COPD patients].
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Disease Progression; Drug Combinations; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolones | 2014 |
Treatment of chronic obstructive pulmonary disease by dual bronchodilation with coformulation of indacaterol/glycopyrronium.
Topics: Acetylcholine; Bronchoconstriction; Bronchodilator Agents; Drug Combinations; Glycopyrrolate; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones | 2014 |
Glycopyrronium bromide for the treatment of chronic obstructive pulmonary disease.
Topics: Bronchodilator Agents; Drug Administration Schedule; Glycopyrrolate; Humans; Lung; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Recovery of Function; Severity of Illness Index; Treatment Outcome | 2015 |
Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Animals; Bronchodilator Agents; Drug Combinations; Glycopyrrolate; Humans; Indans; Lung; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Severity of Illness Index; Treatment Outcome | 2015 |
Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Drug Combinations; Glycopyrrolate; Humans; Indans; Lung; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Treatment Outcome | 2015 |
Long-acting muscarinic antagonists for the prevention of exacerbations of chronic obstructive pulmonary disease.
Topics: Clinical Trials as Topic; Delayed-Action Preparations; Glycopyrrolate; Humans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Tiotropium Bromide; Tropanes | 2015 |
QVA149 (indacaterol/glycopyrronium) for the treatment of chronic obstructive pulmonary disease.
Topics: Administration, Inhalation; Bronchodilator Agents; Clinical Trials, Phase III as Topic; Drug Combinations; Dyspnea; Glycopyrrolate; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolones | 2015 |
Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Drug Administration Schedule; Drug Combinations; Evidence-Based Medicine; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Japan; Lung; Muscarinic Antagonists; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinolones; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome | 2015 |
[Are there cardiovascular adverse effects of inhaled anticholinergics?].
Topics: Administration, Inhalation; Bronchodilator Agents; Cardiovascular Diseases; Cardiovascular System; Cholinergic Antagonists; Clinical Trials as Topic; Glycopyrrolate; Humans; Incidence; Ipratropium; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Risk Factors; Scopolamine Derivatives; Tiotropium Bromide | 2015 |
Clinical role of dual bronchodilation with an indacaterol-glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of life.
Topics: Adrenergic alpha-2 Receptor Agonists; Bronchodilator Agents; Drug Combinations; Glycopyrrolate; Humans; Indans; Lung; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolones; Treatment Outcome | 2015 |
Comparative efficacy of combination bronchodilator therapies in COPD: a network meta-analysis.
Topics: Bronchodilator Agents; Drug Combinations; Drug Therapy, Combination; Dyspnea; Forced Expiratory Volume; Formoterol Fumarate; Glycopyrrolate; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones; Randomized Controlled Trials as Topic; Salmeterol Xinafoate; Tiotropium Bromide; Treatment Outcome | 2015 |
Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis.
Topics: Aged; Bayes Theorem; Bronchodilator Agents; Drug Administration Schedule; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Lung; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinuclidines; Randomized Controlled Trials as Topic; Recovery of Function; Spirometry; Surveys and Questionnaires; Time Factors; Tiotropium Bromide; Treatment Outcome; Tropanes | 2015 |
Once-daily glycopyrronium bromide (Seebri Breezhaler(®)) for the treatment of chronic obstructive pulmonary disease (COPD).
Topics: Administration, Inhalation; Bronchodilator Agents; Dyspnea; Exercise Tolerance; Glycopyrrolate; Humans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive | 2015 |
Effect of tiotropium on COPD exacerbations: A systematic review.
Topics: Administration, Inhalation; Bronchodilator Agents; Cholinergic Antagonists; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Randomized Controlled Trials as Topic; Tiotropium Bromide | 2016 |
[LAMA/LABA fixed dose combination for treatment of COPD].
Topics: Adrenergic beta-2 Receptor Agonists; Benzoxazines; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Delayed-Action Preparations; Drug Combinations; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Quinuclidines; Respiratory Function Tests; Tiotropium Bromide; Treatment Outcome | 2016 |
NVA237, a long-acting muscarinic antagonist, as an emerging therapy for chronic obstructive pulmonary disease.
Topics: Bronchodilator Agents; Delayed-Action Preparations; Glycopyrrolate; Humans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Receptor, Muscarinic M3; Scopolamine Derivatives; Tiotropium Bromide | 2011 |
Once-daily glycopyrronium bromide, a long-acting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit.
Topics: Administration, Inhalation; Bronchodilator Agents; Drug Administration Schedule; Exercise Tolerance; Forced Expiratory Volume; Glycopyrrolate; Humans; Lung; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Recovery of Function; Treatment Outcome | 2012 |
Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD.
Topics: Administration, Inhalation; Bronchodilator Agents; Drug Administration Schedule; Exercise Tolerance; Glycopyrrolate; Humans; Lung; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Severity of Illness Index; Time Factors; Treatment Outcome | 2012 |
100 trial(s) available for glycopyrrolate and Airflow Obstruction, Chronic
| Article | Year |
|---|---|
Relationship between prior inhaled corticosteroid use and benefits ofbudesonide/glycopyrronium/formoterol fumarate dihydrate on exacerbations, symptoms, health-related quality of life, and lung function in patients with chronic obstructive pulmonary disea
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Bronchodilator Agents; Budesonide; Double-Blind Method; Drug Combinations; Formoterol Fumarate; Glycopyrrolate; Humans; Lung; Metered Dose Inhalers; Pulmonary Disease, Chronic Obstructive; Quality of Life | 2022 |
Bronchodilators in Tobacco-Exposed Persons with Symptoms and Preserved Lung Function.
Topics: Adrenergic beta-2 Receptor Agonists; Anti-Bacterial Agents; Bronchodilator Agents; Forced Expiratory Volume; Glucocorticoids; Glycopyrrolate; Humans; Lung; Nicotiana; Pulmonary Disease, Chronic Obstructive; Treatment Outcome | 2022 |
Effects of long-acting bronchodilators on cardiac autonomic control in COPD.
Topics: Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Glycopyrrolate; Humans; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Tiotropium Bromide | 2022 |
Benefits of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate on COPD Exacerbations, Lung Function, Symptoms, and Quality of Life Across Blood Eosinophil Ranges: A Post-Hoc Analysis of Data from ETHOS.
Topics: Administration, Inhalation; Bronchodilator Agents; Budesonide; Double-Blind Method; Drug Combinations; Formoterol Fumarate; Glycopyrrolate; Humans; Lung; Pulmonary Disease, Chronic Obstructive; Quality of Life | 2022 |
Pharmacokinetics of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler formulated using co-suspension delivery technology after single and chronic dosing in patients with COPD.
Topics: Administration, Inhalation; Adult; Aged; Aged, 80 and over; Bronchodilator Agents; Budesonide; Double-Blind Method; Drug Combinations; Drug Delivery Systems; Female; Formoterol Fumarate; Glycopyrrolate; Humans; Male; Metered Dose Inhalers; Middle Aged; Pulmonary Disease, Chronic Obstructive; Random Allocation | 2020 |
Long-Term Safety and Efficacy of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD.
Topics: Bronchodilator Agents; Budesonide; Double-Blind Method; Drug Combinations; Drug Monitoring; Drug Tolerance; Female; Formoterol Fumarate; Glycopyrrolate; Humans; Japan; Male; Metered Dose Inhalers; Middle Aged; Pulmonary Disease, Chronic Obstructive; Respiratory Function Tests; Severity of Illness Index; Time; Treatment Outcome | 2019 |
Efficacy And Safety Of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (GFF MDI) Formulated Using Co-Suspension Delivery Technology In Chinese Patients With COPD.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Bronchodilator Agents; China; Double-Blind Method; Drug Combinations; Female; Forced Expiratory Volume; Formoterol Fumarate; Glycopyrrolate; Humans; Lung; Male; Metered Dose Inhalers; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Recovery of Function; Severity of Illness Index; Time Factors; Treatment Outcome | 2020 |
Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler in Chinese Patients with COPD: A Subgroup Analysis of KRONOS.
Topics: Administration, Inhalation; Adult; Aged; Bronchodilator Agents; Budesonide; China; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Forced Expiratory Volume; Formoterol Fumarate; Glycopyrrolate; Humans; Male; Metered Dose Inhalers; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quality of Life; Respiratory Function Tests | 2020 |
Glycopyrrolate/formoterol fumarate metered dose inhaler for maintenance-naïve patients with chronic obstructive pulmonary disease: a post-hoc analysis of the randomized PINNACLE trials.
Topics: Administration, Inhalation; Aged; Bronchodilator Agents; Double-Blind Method; Drug Therapy, Combination; Female; Formoterol Fumarate; Glycopyrrolate; Humans; Internationality; Male; Metered Dose Inhalers; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive | 2020 |
Impact of baseline symptoms and health status on COPD exacerbations in the FLAME study.
Topics: Aged; Bronchodilator Agents; Disease Progression; Double-Blind Method; Drug Combinations; Female; Fluticasone-Salmeterol Drug Combination; Forced Expiratory Volume; Glycopyrrolate; Health Status; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Surveys and Questionnaires | 2020 |
Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Aged; Aged, 80 and over; Budesonide; Double-Blind Method; Drug Combinations; Female; Forced Expiratory Volume; Formoterol Fumarate; Glucocorticoids; Glycopyrrolate; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive | 2020 |
Effectiveness and Tolerability of LABA/LAMA Fixed-Dose Combinations Aclidinium/Formoterol, Glycopyrronium/Indacaterol and Umeclidinium/Vilanterol in the Treatment of COPD in Daily Practice - Results of the Non-Interventional DETECT Study.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Drug Combinations; Formoterol Fumarate; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolones; Quinuclidines; Treatment Outcome | 2020 |
Early Clinically Important Improvement (ECII) and Exacerbation Outcomes in COPD Patients.
Topics: Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Double-Blind Method; Forced Expiratory Volume; Glycopyrrolate; Humans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Treatment Outcome | 2020 |
Long-acting dual bronchodilator therapy (indacaterol/glycopyrronium) versus nebulized short-acting dual bronchodilator (salbutamol/ipratropium) in chronic obstructive pulmonary disease: A double-blind, randomized, placebo-controlled trial.
Topics: Administration, Inhalation; Aged; Albuterol; Bronchodilator Agents; Cross-Over Studies; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Glycopyrrolate; Humans; Indans; Ipratropium; Male; Metered Dose Inhalers; Middle Aged; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinolones; Treatment Outcome | 2020 |
Efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler delivered using co-suspension delivery technology in Japanese patients with moderate-to-very severe chronic obstructive pulmonary disease.
Topics: Administration, Inhalation; Adult; Aged; Aged, 80 and over; Asian People; Delayed-Action Preparations; Double-Blind Method; Drug Delivery Systems; Female; Formoterol Fumarate; Glycopyrrolate; Humans; Male; Metered Dose Inhalers; Middle Aged; Pulmonary Disease, Chronic Obstructive; Safety; Severity of Illness Index; Suspensions; Treatment Outcome | 2021 |
Ethnic pharmacokinetic comparison of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) between Asian and Western healthy subjects.
Topics: Administration, Inhalation; Bronchodilator Agents; Budesonide; Double-Blind Method; Drug Combinations; Formoterol Fumarate; Fumarates; Glycopyrrolate; Healthy Volunteers; Humans; Metered Dose Inhalers; Pulmonary Disease, Chronic Obstructive | 2020 |
Efficacy and Safety of Inhaled Glycopyrronium Bromide in COPD: A Randomized, Parallel Group, Dose-Ranging Study (GLIMMER).
Topics: Administration, Inhalation; Adult; Bronchodilator Agents; Double-Blind Method; Forced Expiratory Volume; Formoterol Fumarate; Glycopyrrolate; Humans; Pulmonary Disease, Chronic Obstructive; Tiotropium Bromide; Treatment Outcome | 2021 |
Functional respiratory imaging assessment of budesonide/glycopyrrolate/formoterol fumarate and glycopyrrolate/formoterol fumarate metered dose inhalers in patients with COPD: the value of inhaled corticosteroids.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Bronchodilator Agents; Budesonide; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Formoterol Fumarate; Glycopyrrolate; Humans; Male; Metered Dose Inhalers; Middle Aged; Pulmonary Disease, Chronic Obstructive; Tomography, X-Ray Computed | 2021 |
[Study of the month : FLAME study in chronic obstructive pulmonary disease].
Topics: Administration, Inhalation; Aged; Bronchodilator Agents; Female; Fluticasone; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Salmeterol Xinafoate; Treatment Outcome | 2016 |
Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial.
Topics: Administration, Inhalation; Adult; Aged; Beclomethasone; Bronchodilator Agents; Double-Blind Method; Female; Forced Expiratory Volume; Formoterol Fumarate; Glucocorticoids; Glycopyrrolate; Humans; Male; Middle Aged; Muscarinic Antagonists; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Tiotropium Bromide | 2017 |
Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with chronic obstructive pulmonary disease.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Bronchodilator Agents; Drug Therapy, Combination; Drug Tolerance; Dyspnea; Female; Forced Expiratory Volume; Formoterol Fumarate; Glycopyrrolate; Humans; Male; Metered Dose Inhalers; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Severity of Illness Index; Smoking; Tiotropium Bromide; Treatment Outcome | 2017 |
Response to Indacaterol/Glycopyrronium (IND/GLY) by Sex in Patients with COPD: A Pooled Analysis from the IGNITE Program.
Topics: Aged; Bronchodilator Agents; Drug Combinations; Dyspnea; Female; Fluticasone-Salmeterol Drug Combination; Forced Expiratory Volume; Glucocorticoids; Glycopyrrolate; Health Status; Humans; Indans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Severity of Illness Index; Sex Factors; Tiotropium Bromide; Vital Capacity | 2017 |
Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial.
Topics: Adrenergic beta-2 Receptor Agonists; Adult; Aged; Bronchodilator Agents; Disease Progression; Drug Combinations; Drug Substitution; Dyspnea; Europe; Female; Forced Expiratory Volume; Glycopyrrolate; Health Status; Humans; Indans; Lung; Male; Middle Aged; Muscarinic Antagonists; Patient Safety; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolones; Recovery of Function; Risk Factors; Severity of Illness Index; Time Factors; Treatment Outcome | 2017 |
Baseline Symptom Score Impact on Benefits of Glycopyrrolate/Formoterol Metered Dose Inhaler in COPD.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Forced Expiratory Volume; Formoterol Fumarate; Glycopyrrolate; Humans; Male; Metered Dose Inhalers; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Severity of Illness Index; Treatment Outcome | 2017 |
Bronchodilator efficacy of extrafine glycopyrronium bromide: the Glyco 2 study.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Aged; Albuterol; Bronchodilator Agents; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; England; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Ipratropium; Lung; Male; Middle Aged; Muscarinic Antagonists; Particle Size; Pulmonary Disease, Chronic Obstructive; Severity of Illness Index; Time Factors; Tiotropium Bromide; Treatment Outcome | 2017 |
24-h bronchodilation and inspiratory capacity improvements with glycopyrrolate/formoterol fumarate via co-suspension delivery technology in COPD.
Topics: Aged; Bronchodilator Agents; Cross-Over Studies; Double-Blind Method; Drug Delivery Systems; Drug Therapy, Combination; Female; Formoterol Fumarate; Glycopyrrolate; Humans; Inspiratory Capacity; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Time Factors | 2017 |
Long-term safety of glycopyrrolate/eFlow
Topics: Administration, Inhalation; Aged; Bronchodilator Agents; Cough; Female; Forced Expiratory Volume; Gastrointestinal Diseases; Glycopyrrolate; Headache; Humans; Male; Middle Aged; Muscarinic Antagonists; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Respiratory Tract Infections; Severity of Illness Index; Tiotropium Bromide; Vital Capacity | 2017 |
Dual Bronchodilation with Indacaterol Maleate/Glycopyrronium Bromide Compared with Umeclidinium Bromide/Vilanterol in Patients with Moderate-to-Severe COPD: Results from Two Randomized, Controlled, Cross-over Studies.
Topics: Aged; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Cross-Over Studies; Double-Blind Method; Drug Combinations; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Quinuclidines; Severity of Illness Index | 2017 |
Dose selection for glycopyrrolate/eFlow
Topics: Aged; Bronchodilator Agents; Dose-Response Relationship, Drug; Female; Glycopyrrolate; Humans; Male; Middle Aged; Muscarinic Antagonists; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive | 2017 |
Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population.
Topics: Aged; Cost-Benefit Analysis; Double-Blind Method; Drug Combinations; Female; Fluticasone-Salmeterol Drug Combination; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Models, Economic; Population Surveillance; Pulmonary Disease, Chronic Obstructive; Quinolones; Sweden | 2017 |
Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study.
Topics: Administration, Inhalation; Administration, Oral; Aged; Albuterol; Aminopyridines; Benzamides; Cyclopropanes; Drug Therapy, Combination; Exercise Tolerance; Female; Glucocorticoids; Glycopyrrolate; Humans; Lung Volume Measurements; Male; Middle Aged; Muscarinic Antagonists; Phosphodiesterase 4 Inhibitors; Pilot Projects; Pregnenediones; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Severity of Illness Index | 2018 |
Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Beclomethasone; Bronchodilator Agents; Double-Blind Method; Drug Therapy, Combination; Female; Formoterol Fumarate; Glucocorticoids; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones | 2018 |
A phase IIb randomized, chronic-dosing, incomplete block, cross-over study of glycopyrronium, delivered via metered dose inhaler, compared with a placebo and an active control in patients with moderate-to-severe COPD.
Topics: Administration, Inhalation; Adult; Aged; Aged, 80 and over; Bronchodilator Agents; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Drug Delivery Systems; Female; Glycopyrrolate; Humans; Male; Metered Dose Inhalers; Middle Aged; Muscarinic Antagonists; Placebo Effect; Pulmonary Disease, Chronic Obstructive; Severity of Illness Index | 2018 |
Pharmacokinetics of glycopyrronium/formoterol fumarate dihydrate delivered via metered dose inhaler using co-suspension delivery technology in patients with moderate-to-very severe COPD.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Aged; Aged, 80 and over; Australia; Biological Availability; Bronchodilator Agents; Double-Blind Method; Drug Combinations; Female; Formoterol Fumarate; Glycopyrrolate; Humans; Lung; Male; Metered Dose Inhalers; Middle Aged; Muscarinic Antagonists; New Zealand; Pulmonary Disease, Chronic Obstructive; Severity of Illness Index; Treatment Outcome; United States | 2018 |
Early Changes in eDiary COPD Symptoms Predict Clinically Relevant Treatment Response at 12 Weeks: Analysis from the CRYSTAL Study.
Topics: Aged; Bronchodilator Agents; Drug Combinations; Dyspnea; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Patient Reported Outcome Measures; Prognosis; Pulmonary Disease, Chronic Obstructive; Quinolones; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2018 |
Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Aged; Bronchodilator Agents; Double-Blind Method; Female; Fluticasone-Salmeterol Drug Combination; Glucocorticoids; Glycopyrrolate; Humans; Indans; Male; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Tiotropium Bromide; Treatment Outcome | 2018 |
Dose-response of an extrafine dry powder inhaler formulation of glycopyrronium bromide: randomized, double-blind, placebo-controlled, dose-ranging study (GlycoNEXT).
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Area Under Curve; Bronchodilator Agents; Cross-Over Studies; Czech Republic; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Dry Powder Inhalers; Female; Forced Expiratory Volume; Germany; Glycopyrrolate; Humans; Hungary; Lactation; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Romania; Treatment Outcome | 2018 |
Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study.
Topics: Aged; Bronchodilator Agents; Disease Progression; Double-Blind Method; Drug Combinations; Female; Fluticasone-Salmeterol Drug Combination; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones | 2018 |
Efficacy and safety of four doses of glycopyrrolate/formoterol fumarate delivered via a metered dose inhaler compared with the monocomponents in patients with moderate-to-severe COPD.
Topics: Administration, Inhalation; Adult; Aged; Aged, 80 and over; Area Under Curve; Bronchodilator Agents; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Female; Forced Expiratory Volume; Formoterol Fumarate; Glycopyrrolate; Humans; Male; Metered Dose Inhalers; Middle Aged; Muscarinic Antagonists; Nutrition Surveys; Pulmonary Disease, Chronic Obstructive; Reproducibility of Results; Severity of Illness Index | 2018 |
Capturing Exacerbations of Chronic Obstructive Pulmonary Disease with EXACT. A Subanalysis of FLAME.
Topics: Bronchodilator Agents; Disease Progression; Drug Therapy, Combination; Female; Fluticasone; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Risk Factors; Salmeterol Xinafoate; Surveys and Questionnaires | 2019 |
Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: The FLASH randomized controlled trial.
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Bronchodilator Agents; Double-Blind Method; Drug Combinations; Drug Monitoring; Drug Substitution; Female; Fluticasone-Salmeterol Drug Combination; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Respiratory Function Tests; Treatment Outcome | 2018 |
A randomized study using functional respiratory imaging to characterize bronchodilator effects of glycopyrrolate/formoterol fumarate delivered by a metered dose inhaler using co-suspension delivery technology in patients with COPD.
Topics: Administration, Inhalation; Adult; Aged; Aged, 80 and over; Belgium; Bronchodilator Agents; Double-Blind Method; Forced Expiratory Volume; Formoterol Fumarate; Germany; Glycopyrrolate; Humans; London; Male; Metered Dose Inhalers; Middle Aged; Pulmonary Disease, Chronic Obstructive; Respiration; Treatment Outcome | 2018 |
An Open-Label Study Evaluating the Performance of the Dose Indicator in a Metered Dose Inhaler Delivering Glycopyrrolate and Formoterol Fumarate in Patients with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Aged; Aged, 80 and over; Bronchodilator Agents; Drug Combinations; Equipment Design; Female; Formoterol Fumarate; Glycopyrrolate; Humans; Lung; Male; Metered Dose Inhalers; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Severity of Illness Index; Treatment Outcome; United States | 2019 |
Satisfaction with the Use of eFlow Closed-System Nebulizer in Patients with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: Findings from a Long-Term Safety Study.
Topics: Administration, Inhalation; Aged; Bronchodilator Agents; Equipment Design; Female; Glycopyrrolate; Humans; Lung; Male; Middle Aged; Muscarinic Antagonists; Nebulizers and Vaporizers; Patient Satisfaction; Pulmonary Disease, Chronic Obstructive; Severity of Illness Index; Time Factors; Tiotropium Bromide; Treatment Outcome | 2019 |
Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME study.
Topics: Aged; Bronchodilator Agents; Disease Progression; Double-Blind Method; Drug Combinations; Female; Fluticasone-Salmeterol Drug Combination; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Sex Characteristics; Treatment Outcome | 2019 |
Extrafine triple therapy in patients with symptomatic COPD and history of one moderate exacerbation.
Topics: Administration, Inhalation; Beclomethasone; Bronchodilator Agents; Drug Combinations; Forced Expiratory Volume; Formoterol Fumarate; Glycopyrrolate; Humans; Pulmonary Disease, Chronic Obstructive; Treatment Outcome | 2019 |
A Randomized, Double-Blind, Double-Dummy Study of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Relative to Umeclidinium/Vilanterol Dry Powder Inhaler in COPD.
Topics: Administration, Inhalation; Aged; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Double-Blind Method; Dry Powder Inhalers; Female; Forced Expiratory Volume; Formoterol Fumarate; Glycopyrrolate; Humans; Male; Metered Dose Inhalers; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Respiratory Function Tests; Treatment Outcome | 2019 |
Bone and ocular safety of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a 52-week randomized study.
Topics: Aged; Anti-Asthmatic Agents; Bone Density; Bronchodilator Agents; Budesonide, Formoterol Fumarate Drug Combination; Cataract; Double-Blind Method; Female; Glycopyrrolate; Humans; Intraocular Pressure; Lens, Crystalline; Male; Metered Dose Inhalers; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive | 2019 |
Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study.
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Bronchodilator Agents; Double-Blind Method; Drug Combinations; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Male; Medication Adherence; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Spirometry; Treatment Outcome; Vital Capacity | 2013 |
Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Bronchodilator Agents; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Lung; Male; Middle Aged; Muscarinic Antagonists; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinolones; Severity of Illness Index; Time Factors; Treatment Outcome | 2013 |
Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study.
Topics: Adult; Aged; Area Under Curve; Bronchodilator Agents; Cross-Over Studies; Drug Combinations; Dyspnea; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Powders; Pulmonary Disease, Chronic Obstructive; Quinolones; Scopolamine Derivatives; Spirometry; Tiotropium Bromide; Treatment Outcome | 2014 |
Combined long-acting bronchodilator single therapy for COPD.
Topics: Bronchodilator Agents; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Male; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinolones | 2014 |
Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study.
Topics: Administration, Inhalation; Albuterol; Androstadienes; Bronchodilator Agents; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Fluticasone-Salmeterol Drug Combination; Glucocorticoids; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Sympathomimetics; Treatment Outcome | 2013 |
Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study.
Topics: Administration, Inhalation; Aged; Bronchodilator Agents; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Drug Monitoring; Female; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Respiratory Function Tests; Respiratory System; Scopolamine Derivatives; Severity of Illness Index; Tiotropium Bromide; Treatment Outcome | 2013 |
A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study.
Topics: Double-Blind Method; Drug Administration Schedule; Female; Glycopyrrolate; Humans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Scopolamine Derivatives; Tiotropium Bromide | 2014 |
Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study.
Topics: Adult; Aged; Bronchodilator Agents; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Exercise Tolerance; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Lung Volume Measurements; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Scopolamine Derivatives; Spirometry; Tiotropium Bromide; Treatment Outcome; Vital Capacity | 2014 |
Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Area Under Curve; Bronchodilator Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Europe; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Inspiratory Capacity; Lung; Male; Middle Aged; Muscarinic Antagonists; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinolones; Severity of Illness Index; Time Factors; Treatment Outcome; Vital Capacity | 2014 |
Randomized study of the safety, pharmacokinetics, and bronchodilatory efficacy of a proprietary glycopyrronium metered-dose inhaler in study patients with chronic obstructive pulmonary disease.
Topics: Adult; Aged; Area Under Curve; Bronchodilator Agents; Cross-Over Studies; Double-Blind Method; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Male; Metered Dose Inhalers; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Scopolamine Derivatives; Tiotropium Bromide; Xerostomia | 2014 |
Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients.
Topics: Aged; Bronchodilator Agents; Drug Combinations; Drug Therapy, Combination; Female; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Risk Factors; Scopolamine Derivatives; Tiotropium Bromide; Treatment Outcome | 2014 |
Translational Study Searching for Synergy between Glycopyrronium and Indacaterol.
Topics: Administration, Inhalation; Aged; Aged, 80 and over; Bronchi; Bronchodilator Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Single-Blind Method; Translational Research, Biomedical; Treatment Outcome | 2015 |
Efficacy and safety of nebulized glycopyrrolate for administration using a high efficiency nebulizer in patients with chronic obstructive pulmonary disease.
Topics: Administration, Inhalation; Adult; Aged; Blood Pressure; Bronchodilator Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Equipment Design; Female; Glycopyrrolate; Heart Rate; Humans; Male; Middle Aged; Muscarinic Antagonists; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Respiratory Function Tests; Severity of Illness Index | 2015 |
Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting.
Topics: Aged; Albuterol; Androstadienes; Bronchodilator Agents; Cost-Benefit Analysis; Double-Blind Method; Drug Combinations; Drug Costs; Drug Therapy, Combination; Female; Fluticasone; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Monte Carlo Method; Pulmonary Disease, Chronic Obstructive; Quinolones; Salmeterol Xinafoate; Sweden | 2014 |
The Prospective Non-Interventional DACCORD Study in the National COPD Registry in Germany: design and methods.
Topics: Adrenergic beta-2 Receptor Agonists; Adult; Bronchodilator Agents; Female; Follow-Up Studies; Germany; Glycopyrrolate; Humans; Male; Outpatients; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Registries; Treatment Outcome | 2015 |
Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study.
Topics: Adult; Aged; Asian People; Bronchodilator Agents; China; Double-Blind Method; Drug Administration Schedule; Dyspnea; Female; Forced Expiratory Volume; Glycopyrrolate; Health Status; Humans; India; Lung; Male; Middle Aged; Muscarinic Antagonists; Philippines; Pulmonary Disease, Chronic Obstructive; Recovery of Function; Republic of Korea; Severity of Illness Index; Spirometry; Surveys and Questionnaires; Time Factors; Treatment Outcome; Vital Capacity | 2015 |
Glycopyrronium + indacaterol. A fixed-dose combination with no advantages in COPD.
Topics: Adrenergic beta-2 Receptor Agonists; Double-Blind Method; Drug Therapy, Combination; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones | 2014 |
Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study.
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Bronchodilator Agents; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Ethanolamines; Female; Forced Expiratory Volume; Formoterol Fumarate; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolones; Scopolamine Derivatives; Tiotropium Bromide; Treatment Outcome; Vital Capacity | 2015 |
Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trial.
Topics: Administration, Inhalation; Aged; Albuterol; Androstadienes; Australia; Bronchodilator Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluticasone; Forced Expiratory Volume; Glycopyrrolate; Health Status; Humans; Male; Middle Aged; New Zealand; Pulmonary Disease, Chronic Obstructive; Risk Factors; Salmeterol Xinafoate; Scopolamine Derivatives; Severity of Illness Index; Surveys and Questionnaires; Tiotropium Bromide; Treatment Outcome | 2015 |
Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi.
Topics: Administration, Inhalation; Bronchi; Bronchoconstriction; Bronchodilator Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; In Vitro Techniques; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Time Factors; Tiotropium Bromide; Treatment Outcome; Tropanes | 2015 |
LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Aged; Bronchodilator Agents; Double-Blind Method; Drug Combinations; Female; Fluticasone-Salmeterol Drug Combination; Forced Expiratory Volume; Glucocorticoids; Glycopyrrolate; Humans; Indans; Lung; Male; Middle Aged; Muscarinic Antagonists; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinolones; Recovery of Function; Severity of Illness Index; Spirometry; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2015 |
FLIGHT1 and FLIGHT2: Efficacy and Safety of QVA149 (Indacaterol/Glycopyrrolate) versus Its Monocomponents and Placebo in Patients with Chronic Obstructive Pulmonary Disease.
Topics: Bronchodilator Agents; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome | 2015 |
[LAMA/LABA or LABA/ICS?].
Topics: Administration, Inhalation; Drug Therapy, Combination; Fluticasone; Forced Expiratory Volume; Glycopyrrolate; Indans; Lung Volume Measurements; Pulmonary Disease, Chronic Obstructive; Quinolones; Salmeterol Xinafoate | 2015 |
Faster reduction in hyperinflation and improvement in lung ventilation inhomogeneity promoted by aclidinium compared to glycopyrronium in severe stable COPD patients. A randomized crossover study.
Topics: Aged; Aged, 80 and over; Bronchodilator Agents; Cross-Over Studies; Double-Blind Method; Dyspnea; Endpoint Determination; Female; Glycopyrrolate; Humans; Lung; Male; Middle Aged; Plethysmography; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Residual Volume; Respiratory Function Tests; Tropanes | 2015 |
Bronchodilator effects, pharmacokinetics and safety of PSX1002-GB, a novel glycopyrronium bromide formulation, in COPD patients; a randomised crossover study.
Topics: Aged; Bronchodilator Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Male; Metered Dose Inhalers; Middle Aged; Pulmonary Disease, Chronic Obstructive; Time Factors; Treatment Outcome | 2016 |
[LAMA/LABA supports physical activity in COPD patients].
Topics: Drug Combinations; Glycopyrrolate; Humans; Indans; Motor Activity; Pulmonary Disease, Chronic Obstructive; Quinolones | 2016 |
The bronchodilator effects of extrafine glycopyrronium added to combination treatment with beclometasone dipropionate plus formoterol in COPD: A randomised crossover study (the TRIDENT study).
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Beclomethasone; Bronchodilator Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Forced Expiratory Volume; Formoterol Fumarate; Glucocorticoids; Glycopyrrolate; Humans; Male; Metered Dose Inhalers; Middle Aged; Muscarinic Antagonists; Predictive Value of Tests; Pulmonary Disease, Chronic Obstructive; Treatment Outcome; Vital Capacity | 2016 |
Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Double-Blind Method; Drug Combinations; Female; Fluticasone-Salmeterol Drug Combination; Glucocorticoids; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones | 2016 |
Long-term safety of glycopyrrolate: A randomized study in patients with moderate-to-severe COPD (GEM3).
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Bronchodilator Agents; Double-Blind Method; Electrocardiography; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Severity of Illness Index; Treatment Outcome; United States; Vital Capacity; Vital Signs | 2016 |
[Dual bronchodilators becomes the first choice combination].
Topics: Adrenergic beta-2 Receptor Agonists; Double-Blind Method; Drug Combinations; Fluticasone; Glycopyrrolate; Guideline Adherence; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Salmeterol Xinafoate | 2016 |
Effects of indacaterol/glycopyrronium (QVA149) on lung hyperinflation and physical activity in patients with moderate to severe COPD: a randomised, placebo-controlled, crossover study (The MOVE Study).
Topics: Aged; Bronchodilator Agents; Cross-Over Studies; Double-Blind Method; Drug Combinations; Exercise; Female; Forced Expiratory Volume; Germany; Glycopyrrolate; Humans; Indans; Inspiratory Capacity; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones | 2016 |
Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study.
Topics: Administration, Inhalation; Aged; Bronchodilator Agents; Double-Blind Method; Drug Administration Schedule; Dyspnea; Female; Forced Expiratory Volume; Glycopyrrolate; Health Status; Humans; Lung; Male; Middle Aged; Muscarinic Antagonists; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Severity of Illness Index; Spirometry; Surveys and Questionnaires; Time Factors; Treatment Outcome; United States | 2016 |
Efficacy of Double Bronchodilation (LABA+LAMA) in Patients with Chronic Obstructive Pulmonary Disease (COPD) and Lung Cancer.
Topics: Adenocarcinoma; Adrenergic beta-2 Receptor Agonists; Aged; Bronchodilator Agents; Carcinoma, Squamous Cell; Delayed-Action Preparations; Female; Glycopyrrolate; Humans; Indans; Lung Neoplasms; Male; Middle Aged; Muscarinic Antagonists; Pilot Projects; Pneumonectomy; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Quinolones | 2016 |
Early bronchodilator action of glycopyrronium versus tiotropium in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and Pulmonary function in the moRnING).
Topics: Administration, Inhalation; Aged; Bronchodilator Agents; Circadian Rhythm; Cross-Over Studies; Drug Administration Schedule; Europe; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Lung; Male; Middle Aged; Muscarinic Antagonists; Patient Reported Outcome Measures; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Quality of Life; Recovery of Function; Severity of Illness Index; Time Factors; Tiotropium Bromide; Treatment Outcome; Vital Capacity | 2016 |
Dose-response to inhaled glycopyrrolate delivered with a novel Co-Suspension™ Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPD.
Topics: Administration, Inhalation; Aged; Bronchodilator Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Equipment Design; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Lung; Male; Maximum Tolerated Dose; Metered Dose Inhalers; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Severity of Illness Index; Time Factors; Treatment Outcome; United States; Vital Capacity | 2016 |
Computed tomography (CT)-assessed bronchodilation induced by inhaled indacaterol and glycopyrronium/indacaterol in COPD.
Topics: Administration, Inhalation; Adrenergic beta-Agonists; Aged; Aged, 80 and over; Bronchi; Bronchodilator Agents; Drug Therapy, Combination; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Japan; Lung; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Respiratory Function Tests; Tomography, X-Ray Computed | 2016 |
A multicenter, randomized, double-blind dose-ranging study of glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler compared to the monocomponents and open-label tiotropium dry powder inhaler in patients with moderate-to-severe CO
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Cholinergic Antagonists; Cross-Over Studies; Double-Blind Method; Drug Combinations; Dry Powder Inhalers; Female; Forced Expiratory Volume; Formoterol Fumarate; Glycopyrrolate; Humans; Male; Metered Dose Inhalers; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Tiotropium Bromide; Treatment Outcome | 2016 |
Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD.
Topics: Administration, Inhalation; Adult; Aged; Aged, 80 and over; Bronchodilator Agents; Budesonide; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Female; Fluticasone; Forced Expiratory Volume; Formoterol Fumarate; Glucocorticoids; Glycopyrrolate; Humans; Male; Metered Dose Inhalers; Middle Aged; Muscarinic Antagonists; Prednisone; Pulmonary Disease, Chronic Obstructive; Suspensions; Vital Capacity | 2017 |
Fast onset of action of glycopyrronium compared with tiotropium in patients with moderate to severe COPD - A randomised, multicentre, crossover trial.
Topics: Administration, Inhalation; Aged; Bronchodilator Agents; Cross-Over Studies; Double-Blind Method; Female; Forced Expiratory Volume; Germany; Glycopyrrolate; Humans; Inspiratory Capacity; Male; Middle Aged; Plethysmography, Whole Body; Pulmonary Disease, Chronic Obstructive; Residual Volume; Severity of Illness Index; Spirometry; Time Factors; Tiotropium Bromide | 2017 |
A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Adult; Aged; Australia; Double-Blind Method; Drug Combinations; Equipment Design; Equipment Failure Analysis; Female; Formoterol Fumarate; Glycopyrrolate; Humans; Male; Metered Dose Inhalers; Middle Aged; Muscarinic Antagonists; New Zealand; Placebo Effect; Pulmonary Disease, Chronic Obstructive; Severity of Illness Index; Treatment Outcome; United States | 2017 |
Indacaterol and glycopyrronium versus indacaterol on body plethysmography measurements in COPD-a randomised controlled study.
Topics: Adrenergic beta-2 Receptor Agonists; Adult; Aged; Aged, 80 and over; Cross-Over Studies; Diagnosis, Computer-Assisted; Double-Blind Method; Drug Combinations; Female; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Muscarinic Antagonists; Placebo Effect; Plethysmography, Whole Body; Pulmonary Disease, Chronic Obstructive; Quinolones; Reproducibility of Results; Respiratory Function Tests; Sensitivity and Specificity; Spirometry; Switzerland; Treatment Outcome | 2017 |
Efficacy and safety of indacaterol/glycopyrronium fixed-dose combination in mild-to-moderate COPD patients symptomatic on tiotropium in Korea: study protocol for a randomized controlled trial.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Cholinergic Antagonists; Clinical Protocols; Drug Administration Schedule; Drug Combinations; Drug Substitution; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Lung; Male; Pulmonary Disease, Chronic Obstructive; Quinolones; Recovery of Function; Republic of Korea; Research Design; Severity of Illness Index; Spirometry; Time Factors; Tiotropium Bromide; Treatment Outcome; Vital Capacity | 2017 |
Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients.
Topics: Administration, Inhalation; Aged; Aged, 80 and over; Bronchodilator Agents; Double-Blind Method; Drug Administration Schedule; Female; Glycopyrrolate; Humans; Male; Middle Aged; Muscarinic Antagonists; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive | 2010 |
Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients.
Topics: Aged; Aged, 80 and over; Bronchodilator Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Scopolamine Derivatives; Time Factors; Tiotropium Bromide; Treatment Outcome | 2010 |
QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease.
Topics: Aged; Bronchodilator Agents; Dose-Response Relationship, Drug; Drug Combinations; Epidemiologic Methods; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Treatment Outcome; Vital Capacity | 2010 |
Bronchodilatory effects of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients.
Topics: Administration, Inhalation; Aged; Aged, 80 and over; Bronchodilator Agents; Cross-Over Studies; Double-Blind Method; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Spirometry; Treatment Outcome | 2011 |
Cardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patients.
Topics: Administration, Inhalation; Aged; Atrial Fibrillation; Blood Pressure; Bronchodilator Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Electrocardiography, Ambulatory; Female; Glycopyrrolate; Heart Rate; Humans; Hyperkalemia; Indans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Tachycardia, Ventricular | 2010 |
Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial.
Topics: Female; Glycopyrrolate; Humans; Male; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quality of Life; Single-Blind Method; Treatment Outcome | 2011 |
Pharmacokinetics of multiple inhaled NVA237 doses in patients with chronic obstructive pulmonary disease (COPD).
Topics: Administration, Inhalation; Aged; Area Under Curve; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glycopyrrolate; Half-Life; Humans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Stereoisomerism | 2012 |
Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial.
Topics: Adult; Aged; Aged, 80 and over; Cross-Over Studies; Drug Administration Schedule; Exercise Test; Exercise Tolerance; Female; Forced Expiratory Volume; Functional Residual Capacity; Glycopyrrolate; Humans; Lung; Lung Volume Measurements; Male; Middle Aged; Muscarinic Antagonists; Plethysmography; Pulmonary Disease, Chronic Obstructive; Recovery of Function; Residual Volume; Severity of Illness Index; Spirometry; Time Factors; Treatment Outcome | 2012 |
Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study.
Topics: Bronchodilator Agents; Double-Blind Method; Female; Glycopyrrolate; Humans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Scopolamine Derivatives; Tiotropium Bromide | 2012 |
A novel model-based approach for dose determination of glycopyrronium bromide in COPD.
Topics: Adult; Aged; Aged, 80 and over; Bronchodilator Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Male; Middle Aged; Models, Biological; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Severity of Illness Index; Time Factors; Treatment Outcome | 2012 |
93 other study(ies) available for glycopyrrolate and Airflow Obstruction, Chronic
| Article | Year |
|---|---|
Real-world Safety and Efficacy of Indacaterol/Glycopyrronium in Japanese Patients with Chronic Obstructive Pulmonary Disease: A 52-week Post-marketing Surveillance.
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Bronchodilator Agents; Drug Combinations; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Japan; Muscarinic Antagonists; Product Surveillance, Postmarketing; Pulmonary Disease, Chronic Obstructive; Quinolones; Treatment Outcome | 2022 |
Which LABA/LAMA should be chosen in COPD patients in real life?
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Drug Combinations; Female; Glycopyrrolate; Humans; Male; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Retrospective Studies; Treatment Outcome | 2021 |
[Fixed combination of mometasone, indacaterol, glycopyrronium for the treatment of severe asthma : Enerzair® Breezhaler®].
Topics: Administration, Inhalation; Asthma; Glycopyrrolate; Humans; Indans; Mometasone Furoate; Pulmonary Disease, Chronic Obstructive; Quinolones | 2021 |
[Fixed combination of budesonide, formoterol, glycopyrronium for the treatment of severe COPD : Trixeo Aerosphere®].
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic Agonists; Bronchodilator Agents; Budesonide; Drug Combinations; Formoterol Fumarate; Glycopyrrolate; Humans; Metered Dose Inhalers; Pulmonary Disease, Chronic Obstructive; Quality of Life | 2022 |
Comparing Clinical Outcomes of Tiotropium/Olodaterol, Umeclidinium/Vilanterol, and Indacaterol/Glycopyrronium Fixed-Dose Combination Therapy in Patients with Chronic Obstructive Pulmonary Disease in Taiwan: A Multicenter Cohort Study.
Topics: Adrenergic beta-2 Receptor Agonists; Benzoxazines; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Drug Combinations; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Quinuclidines; Retrospective Studies; Taiwan; Tiotropium Bromide; Treatment Outcome | 2022 |
Effects of long-acting muscarinic antagonists on promoting ciliary function in airway epithelium.
Topics: Animals; Asthma; Epithelium; Glycopyrrolate; Humans; Mice; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Stroke; Tiotropium Bromide; Trachea | 2022 |
Budesonide/glycopyrronium/formoterol fumarate triple therapy prevents pulmonary hypertension in a COPD mouse model via NFκB inactivation.
Topics: Animals; Bronchodilator Agents; Budesonide; Budesonide, Formoterol Fumarate Drug Combination; Emphysema; Endothelial Cells; Formoterol Fumarate; Fumarates; Glycopyrrolate; Hypertension, Pulmonary; Mice; NF-kappa B; Pancreatic Elastase; Pulmonary Disease, Chronic Obstructive; Pulmonary Emphysema | 2022 |
Cost-Effectiveness Analysis of Triple Therapy with Budesonide/ Glycopyrronium/ Formoterol Fumarate versus Dual Therapy in Patients with Chronic Obstructive Pulmonary Disease in Spain.
Topics: Bronchodilator Agents; Budesonide; Budesonide, Formoterol Fumarate Drug Combination; Cost-Benefit Analysis; Formoterol Fumarate; Fumarates; Glycopyrrolate; Humans; Pulmonary Disease, Chronic Obstructive; Spain | 2022 |
Cost-Effectiveness of Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate versus Dual Therapies in Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease: United Kingdom Analysis Using the ETHOS Study.
Topics: Budesonide; Cost-Benefit Analysis; Formoterol Fumarate; Glycopyrrolate; Humans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quality of Life; State Medicine | 2022 |
Ultrasound assessment of diaphragmatic dynamics in patients with chronic obstructive pulmonary disease after treatment with indacaterol/glycopyrronium.
Topics: Aged; Bronchodilator Agents; Diaphragm; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Lung; Male; Middle Aged; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Treatment Outcome | 2023 |
Chronic Obstructive Pulmonary Disease Exacerbations and Pneumonia Hospitalizations Among New Users of Combination Maintenance Inhalers.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Aged; Bronchodilator Agents; Cohort Studies; Drug Therapy, Combination; Female; Fluticasone; Formoterol Fumarate; Glycopyrrolate; Humans; Male; Muscarinic Antagonists; Nebulizers and Vaporizers; Pneumonia; Pulmonary Disease, Chronic Obstructive | 2023 |
Real-world comparative effectiveness of three single-inhaler dual bronchodilators for the treatment of COPD.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Drug Combinations; Glycopyrrolate; Humans; Muscarinic Antagonists; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Treatment Outcome | 2023 |
Comparative Effectiveness of Umeclidinium/Vilanterol versus Indacaterol/Glycopyrronium on Moderate-to-Severe Exacerbations in Patients with Chronic Obstructive Pulmonary Disease in Clinical Practice in England.
Topics: England; Glycopyrrolate; Humans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Retrospective Studies | 2023 |
The effect of inhaled extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide on distal and central airway indices, assessed using Functional Respiratory Imaging in COPD (DARWiIN).
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Beclomethasone; Bronchodilator Agents; Drug Combinations; Fluticasone-Salmeterol Drug Combination; Formoterol Fumarate; Glycopyrrolate; Humans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive | 2023 |
Exacerbations and Real-World Outcomes After Single-Inhaler Triple Therapy of Budesonide/Glycopyrrolate/Formoterol Fumarate, Among Patients with COPD: Results from the EROS (US) Study.
Topics: Administration, Inhalation; Bronchodilator Agents; Budesonide; Double-Blind Method; Drug Combinations; Formoterol Fumarate; Glycopyrrolate; Humans; Metered Dose Inhalers; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Retrospective Studies | 2023 |
One bronchodilator or two? Translating clinical trials into clinical practice.
Topics: Bronchodilator Agents; Glycopyrrolate; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones; Tiotropium Bromide | 2020 |
Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide: Synergy of triple combination therapy on human airway smooth muscle ex vivo.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Beclomethasone; Bronchodilator Agents; Drug Combinations; Drug Therapy, Combination; Formoterol Fumarate; Glycopyrrolate; Humans; Muscarinic Antagonists; Muscle, Smooth; Pulmonary Disease, Chronic Obstructive | 2020 |
Dual use of bronchodilators versus monotherapy, and its impact on pulmonary rehabilitation in COPD patients.
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Aged, 80 and over; Bronchodilator Agents; Drug Therapy, Combination; Female; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Muscarinic Antagonists; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Quinolones; Tiotropium Bromide | 2020 |
Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Bronchodilator Agents; Clinical Trials, Phase III as Topic; Drug Combinations; Female; Forced Expiratory Volume; Formoterol Fumarate; Glycopyrrolate; Humans; Lung; Male; Metered Dose Inhalers; Middle Aged; Multicenter Studies as Topic; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Randomized Controlled Trials as Topic; Recovery of Function; Severity of Illness Index; Time Factors; Treatment Outcome | 2020 |
COPD clinical control as a predictor of future exacerbations: concept validation in the SPARK study population.
Topics: Aged; Bronchodilator Agents; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Quinolones; Reproducibility of Results; Respiratory Function Tests; Risk Assessment; Severity of Illness Index; Tiotropium Bromide; Treatment Outcome | 2020 |
[Assessment of patient-reported outcomes by questionnaires in patients with Moderate and severe chronic obstructive pulmonary disease treated with glycopyrroniUm in the reaL lifE setTing in Hungary (AMULET)].
Topics: Glycopyrrolate; Humans; Hungary; Patient Reported Outcome Measures; Pulmonary Disease, Chronic Obstructive; Severity of Illness Index | 2020 |
The Effect of Baseline Rescue Medication Use on Efficacy and Safety of Nebulized Glycopyrrolate Treatment in Patients with COPD from the GOLDEN 3 and 4 Studies.
Topics: Administration, Inhalation; Bronchodilator Agents; Double-Blind Method; Forced Expiratory Volume; Glycopyrrolate; Humans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Treatment Outcome | 2020 |
Modelling the Cost-Effectiveness of Indacaterol/Glycopyrronium versus Salmeterol/Fluticasone Using a Novel Markov Exacerbation-Based Approach.
Topics: Bronchodilator Agents; Cost-Benefit Analysis; Drug Combinations; Fluticasone-Salmeterol Drug Combination; Glycopyrrolate; Humans; Indans; Markov Chains; Pulmonary Disease, Chronic Obstructive; Quinolones; Sweden; Treatment Outcome | 2020 |
Effect of Gender on Lung Function and Patient-Reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate.
Topics: Administration, Inhalation; Bronchodilator Agents; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Lung; Male; Muscarinic Antagonists; Nebulizers and Vaporizers; Patient Reported Outcome Measures; Pulmonary Disease, Chronic Obstructive; Quality of Life; Treatment Outcome | 2020 |
Observational Real-World Study to Assess Clinical Characteristics and Device Satisfaction in Patients with COPD Treated with Glycopyrrolate/eFlow
Topics: Administration, Inhalation; Aged; Cross-Sectional Studies; Female; Glycopyrrolate; Humans; Middle Aged; Muscarinic Antagonists; Patient Satisfaction; Personal Satisfaction; Pulmonary Disease, Chronic Obstructive | 2020 |
Sialorrhoea treated with inhaled glycopyrronium.
Topics: Adult; Aged; Glycopyrrolate; Humans; Male; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Sialorrhea | 2021 |
Reigniting the TORCH: Chronic Obstructive Pulmonary Disease Mortality and Inhaled Corticosteroids Revisited.
Topics: Adrenal Cortex Hormones; Budesonide; Double-Blind Method; Formoterol Fumarate; Glycopyrrolate; Humans; Pulmonary Disease, Chronic Obstructive | 2021 |
Reply to López-Campos
Topics: Budesonide; Double-Blind Method; Formoterol Fumarate; Glycopyrrolate; Humans; Pulmonary Disease, Chronic Obstructive | 2021 |
Triple-Therapy Trials for Chronic Obstructive Pulmonary Disease: Methodological Considerations in the Mortality Effect.
Topics: Adult; Aged; Aged, 80 and over; Bronchodilator Agents; Budesonide; Drug Combinations; Female; Formoterol Fumarate; Glycopyrrolate; Humans; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Treatment Outcome | 2021 |
Mortality in ETHOS: A Question of "Power".
Topics: Budesonide; Double-Blind Method; Formoterol Fumarate; Glycopyrrolate; Humans; Pulmonary Disease, Chronic Obstructive | 2021 |
TRICOP - A Real-world effectiveness study with a single-inhaler extrafine triple therapy over 52 weeks in Austrian patients with COPD.
Topics: Administration, Inhalation; Adult; Aged; Aged, 80 and over; Austria; Beclomethasone; Disease Progression; Drug Therapy, Combination; Female; Formoterol Fumarate; Glycopyrrolate; Humans; Male; Middle Aged; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Severity of Illness Index; Time Factors; Treatment Outcome | 2021 |
Comparative Effectiveness and Safety of Different Types of Inhaled Long-Acting β
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aged; Beclomethasone; Benzyl Alcohols; Budesonide, Formoterol Fumarate Drug Combination; Chlorobenzenes; Cohort Studies; Comparative Effectiveness Research; Disease Progression; Drug Combinations; Female; Fluticasone-Salmeterol Drug Combination; Formoterol Fumarate; Glucocorticoids; Glycopyrrolate; Humans; Indans; Male; Muscarinic Antagonists; Pneumonia; Propensity Score; Proportional Hazards Models; Pulmonary Disease, Chronic Obstructive; Quinolones; Quinuclidines | 2021 |
Effects of indacaterol on the LPS-evoked changes in fluid secretion rate and pH in swine tracheal membrane.
Topics: Acetylcholine; Adrenergic beta-2 Receptor Agonists; Animals; Bicarbonates; Bronchodilator Agents; Cell Line, Tumor; Cells, Cultured; Cystic Fibrosis Transmembrane Conductance Regulator; Glycopyrrolate; Humans; Hydrogen-Ion Concentration; Indans; Lipopolysaccharides; Mucins; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Respiratory Mucosa; Swine; Trachea | 2021 |
Effects of (a Combination of) the Beta
Topics: Adrenergic beta-2 Receptor Agonists; Animals; Bronchoconstriction; Bronchodilator Agents; Case-Control Studies; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Female; Glycopyrrolate; Guinea Pigs; Humans; Indans; Lung; Male; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Receptor, Muscarinic M3; Receptors, Adrenergic, beta-2 | 2021 |
Cost-Utility Analysis of Fixed-Dose Combination of Indacaterol Acetate Glycopyrronium Bromide and Mometasone Furoate as a Maintenance Treatment in Adult Patients with Asthma Not Adequately Controlled with a Maintenance Combination of a Long-Acting Beta-Ag
Topics: Acetates; Adrenal Cortex Hormones; Adult; Asthma; Bronchodilator Agents; Cost-Benefit Analysis; Drug Combinations; Glycopyrrolate; Humans; Indans; Mometasone Furoate; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolones; Treatment Outcome | 2021 |
Two cases of chronic obstructive pulmonary disease evaluated by dynamic-ventilatory digital radiography for pulmonary function and assessment of treatment efficacy.
Topics: Aged; Asthma; Bronchodilator Agents; Drug Combinations; Fluticasone; Formoterol Fumarate; Glycopyrrolate; Humans; Indans; Lung; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Radiographic Image Enhancement; Radiography, Thoracic; Spirometry; Tiotropium Bromide; Treatment Outcome | 2021 |
GFF MDI for the improvement of lung function in COPD - A look at the PINNACLE-1 and PINNACLE-2 data and beyond.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Delayed-Action Preparations; Drug Combinations; Drug Delivery Systems; Formoterol Fumarate; Glycopyrrolate; Humans; Metered Dose Inhalers; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive | 2017 |
In vitro dose comparison of Respimat
Topics: Administration, Inhalation; Androstadienes; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Computer Simulation; Drug Combinations; Dry Powder Inhalers; Equipment Design; Glycopyrrolate; Humans; Hydrodynamics; Lung; Metered Dose Inhalers; Models, Anatomic; Muscarinic Antagonists; Pharynx; Pulmonary Disease, Chronic Obstructive; Respiration; Severity of Illness Index; Tiotropium Bromide; Tropanes | 2017 |
Glycopyrrolate (Seebri Neohaler) for Maintenance Therapy in Patients with COPD.
Topics: Administration, Inhalation; Glycopyrrolate; Humans; Maintenance Chemotherapy; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive | 2017 |
GOLD 2017 treatment pathways in 'real life': An analysis of the DACCORD observational study.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Aged; Critical Pathways; Disease Management; Disease Progression; Drug Combinations; Drug Therapy, Combination; Female; Germany; Glycopyrrolate; Humans; Indans; Longitudinal Studies; Maintenance Chemotherapy; Male; Middle Aged; Muscarinic Antagonists; Practice Guidelines as Topic; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Quinolones | 2017 |
Drug Delivery from an Innovative LAMA/LABA Co-suspension Delivery Technology Fixed-Dose Combination MDI: Evidence of Consistency, Robustness, and Reliability.
Topics: Administration, Inhalation; Aerosols; Bronchodilator Agents; Double-Blind Method; Drug Delivery Systems; Formoterol Fumarate; Glycopyrrolate; Humans; Inventions; Metered Dose Inhalers; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Reproducibility of Results; Suspensions | 2018 |
[Evaluation of effect of indacaterol (Onbrez) and/or glycopyrronium (Seebri) treatment on Quality of Life of COPD patients in medical practice in Poland - observational study (OSQO)].
Topics: Aged; Drug Therapy, Combination; Female; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Poland; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolones; Treatment Outcome | 2017 |
In Vitro Characterization of the eFlow Closed System Nebulizer with Glycopyrrolate Inhalation Solution.
Topics: Administration, Inhalation; Aerosols; Glycopyrrolate; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Solutions | 2018 |
Relationship between lung function and inhalation devices for LAMA/LABA therapy for chronic obstructive pulmonary disease.
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Aged, 80 and over; Benzoxazines; Delayed-Action Preparations; Drug Combinations; Dry Powder Inhalers; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Male; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Tiotropium Bromide; Vital Capacity | 2018 |
Single inhaler triple therapy for COPD.
Topics: Beclomethasone; Drug Combinations; Formoterol Fumarate; Glycopyrrolate; Humans; Medication Adherence; Nebulizers and Vaporizers; Practice Guidelines as Topic; Pulmonary Disease, Chronic Obstructive | 2017 |
Cost-effectiveness of indacaterol/glycopyrronium in comparison with salmeterol/fluticasone combination for patients with moderate-to-severe chronic obstructive pulmonary disease: a LANTERN population analysis from Singapore.
Topics: Aged; Bronchodilator Agents; Cohort Studies; Computer Simulation; Cost-Benefit Analysis; Drug Combinations; Drug Costs; Female; Fluticasone-Salmeterol Drug Combination; Forced Expiratory Volume; Glycopyrrolate; Hospitals; Humans; Indans; Male; Middle Aged; Probability; Pulmonary Disease, Chronic Obstructive; Quality-Adjusted Life Years; Quinolones; Singapore | 2018 |
Nebulized glycopyrrolate (Lonhala Magnair) for COPD.
Topics: Administration, Inhalation; Bronchodilator Agents; Glycopyrrolate; Humans; Lung; Muscarinic Antagonists; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Treatment Outcome | 2018 |
Comparison of glycopyrronium versus tiotropium on the time to clinically important deteriorations in patients with COPD: a post-hoc analysis of randomized trials.
Topics: Administration, Inhalation; Aged; Cholinergic Antagonists; Delayed-Action Preparations; Female; Follow-Up Studies; Glycopyrrolate; Humans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Randomized Controlled Trials as Topic; Severity of Illness Index; Tiotropium Bromide; Treatment Outcome; Vital Capacity | 2018 |
Single inhaler triple therapy with extrafine beclomethasone, formoterol, and glycopyrronium for the treatment of chronic obstructive pulmonary disease.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Beclomethasone; Drug Therapy, Combination; Formoterol Fumarate; Glycopyrrolate; Humans; Pulmonary Disease, Chronic Obstructive | 2018 |
Symptomatic COPD: is it time for triple therapy?
Topics: Bronchodilator Agents; Budesonide; Double-Blind Method; Formoterol Fumarate; Glycopyrrolate; Humans; Pulmonary Disease, Chronic Obstructive | 2018 |
Indacaterol/Glycopyrronium versus Salmeterol/Fluticasone in Patients with COPD-A Cost-Effectiveness Analysis in the Czech Republic.
Topics: Bronchodilator Agents; Cost-Benefit Analysis; Czech Republic; Female; Fluticasone-Salmeterol Drug Combination; Glycopyrrolate; Humans; Indans; Male; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quality-Adjusted Life Years; Quinolones | 2018 |
Morbidity and mortality in a population of patients affected by heart failure and chronic obstructive pulmonary disease: an observational study.
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Aged, 80 and over; Bronchodilator Agents; Comorbidity; Drug Combinations; Female; Glycopyrrolate; Heart Failure; Heart Ventricles; Humans; Indans; Italy; Lung; Male; Middle Aged; Muscarinic Antagonists; Patient Readmission; Pulmonary Disease, Chronic Obstructive; Quinolones; Recovery of Function; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2019 |
Improvement in health status with once-daily indacaterol/glycopyrronium 110/50 μg in COPD patients: real-world evidence from an observational study in Ireland.
Topics: Adrenergic beta-2 Receptor Agonists; Adult; Aged; Aged, 80 and over; Bronchodilator Agents; Drug Combinations; Female; Glycopyrrolate; Health Status; Humans; Indans; Ireland; Male; Middle Aged; Muscarinic Antagonists; Prospective Studies; Pulmonary Disease, Chronic Obstructive; Quinolones; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome | 2019 |
Glycopyrrolate (Lonhala Magnair) for Treatment of Chronic Obstructive Pulmonary Disease.
Topics: Administration, Inhalation; Bronchodilator Agents; Forced Expiratory Volume; Glycopyrrolate; Humans; Pulmonary Disease, Chronic Obstructive; Treatment Outcome | 2019 |
Effect of smoking status on lung function, patient-reported outcomes, and safety among patients with COPD treated with indacaterol/glycopyrrolate: Pooled analysis of the FLIGHT1 and FLIGHT2 studies.
Topics: Adult; Aged; Aged, 80 and over; Drug Therapy, Combination; Female; Glycopyrrolate; Humans; Indans; Lung; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Quinolones; Safety; Smoking; Treatment Outcome | 2019 |
Determination of the pharmacokinetics of glycopyrronium in the lung using a population pharmacokinetic modelling approach.
Topics: Absorption; Administration, Inhalation; Biological Availability; Charcoal; Computer Simulation; Drug Administration Schedule; Glycopyrrolate; Healthy Volunteers; Humans; Injections, Intravenous; Lung; Models, Biological; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive | 2013 |
Novartis found to be in breach of code over drug brochure.
Topics: Advertising; Codes of Ethics; Disease Progression; Drug Industry; Drug Labeling; Female; Glycopyrrolate; Humans; Male; Pamphlets; Practice Guidelines as Topic; Pulmonary Disease, Chronic Obstructive | 2013 |
Pipeline for COPD drugs flows with combination candidates.
Topics: Bronchodilator Agents; Drug Combinations; Glycopyrrolate; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones | 2013 |
"All I want for christmas is two": the advent of novel fixed-combination inhalers for COPD and outlook for 2014.
Topics: Administration, Inhalation; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Delayed-Action Preparations; Drug Administration Schedule; Drug Combinations; Forecasting; Glycopyrrolate; Humans; Nebulizers and Vaporizers; Patient Satisfaction; Pulmonary Disease, Chronic Obstructive; Treatment Outcome | 2013 |
Future of fixed-dose longacting β2-agonist and antimuscarinic combination therapy in COPD.
Topics: Albuterol; Androstadienes; Bronchodilator Agents; Drug Combinations; Female; Fluticasone-Salmeterol Drug Combination; Glucocorticoids; Glycopyrrolate; Humans; Indans; Male; Pulmonary Disease, Chronic Obstructive; Quinolones; Sympathomimetics | 2013 |
Inhalation of glycopyrronium inhibits cigarette smoke-induced acute lung inflammation in a murine model of COPD.
Topics: Animals; Anti-Inflammatory Agents; Bronchoalveolar Lavage Fluid; Cytokines; Disease Models, Animal; Female; Glycopyrrolate; Lymphocytes; Macrophages; Matrix Metalloproteinase 9; Mice; Mice, Inbred ICR; Muscarinic Antagonists; Neutrophils; Nicotiana; Oxidative Stress; Pneumonia; Pulmonary Disease, Chronic Obstructive; Smoke; Tissue Inhibitor of Metalloproteinase-1 | 2014 |
COPD treatment: time to change our algorithm?
Topics: Drug Combinations; Female; Glycopyrrolate; Humans; Indans; Male; Pulmonary Disease, Chronic Obstructive; Quinolones; Respiratory System; Scopolamine Derivatives; Tiotropium Bromide | 2013 |
2013 American Thoracic Society International Conference.
Topics: alpha 1-Antitrypsin; alpha 1-Antitrypsin Deficiency; Analgesics, Non-Narcotic; Asthma; Benzamides; Clofazimine; Congresses as Topic; Cyclobutanes; Drug Combinations; Glycopyrrolate; Hospital Mortality; Humans; Indans; Intensive Care Units; Lung; Pulmonary Disease, Chronic Obstructive; Quinolones; Societies, Medical; Thoracic Diseases; Treatment Outcome; Tuberculosis, Multidrug-Resistant; United States | 2013 |
QVA149 versus glycopyrronium for COPD.
Topics: Female; Glycopyrrolate; Humans; Indans; Male; Pulmonary Disease, Chronic Obstructive; Quinolones; Respiratory System; Scopolamine Derivatives | 2013 |
QVA149 versus glycopyrronium for COPD - authors' reply.
Topics: Female; Glycopyrrolate; Humans; Indans; Male; Pulmonary Disease, Chronic Obstructive; Quinolones; Respiratory System; Scopolamine Derivatives | 2013 |
[Glycopyrronium, by inhalation and oral administration (Seebri)].
Topics: Administration, Inhalation; Administration, Oral; Bronchodilator Agents; Glycopyrrolate; Humans; Pulmonary Disease, Chronic Obstructive | 2013 |
Indacaterol for the treatment of chronic obstructive pulmonary disease.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Drug Administration Schedule; Drug Combinations; Glycopyrrolate; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolones; Scopolamine Derivatives; Tiotropium Bromide; Treatment Outcome | 2015 |
Cardiovascular safety of two bronchodilators' fixed-dose combination: indacaterol and glycopyrronium.
Topics: Adjuvants, Anesthesia; Administration, Inhalation; Bronchodilator Agents; Cardiovascular System; Clinical Trials as Topic; Drug Combinations; Glycopyrrolate; Humans; Indans; Pulmonary Disease, Chronic Obstructive; Quinolones | 2015 |
Triple inhaler therapy for COPD.
Topics: Albuterol; Androstadienes; Bronchodilator Agents; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Male; Pulmonary Disease, Chronic Obstructive; Scopolamine Derivatives | 2015 |
Safety of inhaled glycopyrronium in patients with COPD: a comprehensive analysis of clinical studies and post-marketing data.
Topics: Administration, Inhalation; Aged; Aged, 80 and over; Bronchodilator Agents; Female; Glycopyrrolate; Humans; Lung; Male; Middle Aged; Muscarinic Antagonists; Nebulizers and Vaporizers; Patient Safety; Product Surveillance, Postmarketing; Pulmonary Disease, Chronic Obstructive; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Severity of Illness Index; Time Factors; Treatment Outcome | 2015 |
Cost-Effectiveness of Glycopyrronium Bromide Compared with Tiotropium in Patients with Chronic Obstructive Pulmonary Disease in Sweden.
Topics: Bronchodilator Agents; Cost-Benefit Analysis; Female; Forced Expiratory Volume; Glycopyrrolate; Humans; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Sweden; Tiotropium Bromide | 2015 |
[Too positive and uncritical dissemination of Glycopyrronium].
Topics: Glycopyrrolate; Humans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive | 2013 |
[Reply: Good with options].
Topics: Glycopyrrolate; Humans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive | 2013 |
Low Doses of Long-Acting β-Agonists/Long-Acting Muscarinic Agents with Large Effects. The FLIGHT Study.
Topics: Female; Glycopyrrolate; Humans; Indans; Male; Pulmonary Disease, Chronic Obstructive; Quinolones | 2015 |
Response to: impact of tiotropium on exacerbations versus glycopyrronium and QVA149.
Topics: Bronchodilator Agents; Glycopyrrolate; Humans; Lung; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive | 2015 |
Impact of tiotropium on exacerbations versus glycopyrronium and QVA149.
Topics: Bronchodilator Agents; Glycopyrrolate; Humans; Lung; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive | 2015 |
[Good bronchial dilatation helps keep patients physically active].
Topics: Bronchodilator Agents; Clinical Trials as Topic; Drug Combinations; Glycopyrrolate; Humans; Indans; Motor Activity; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinolones | 2016 |
Seebri Neohaler and Utibron Neohaler for COPD.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Bronchodilator Agents; Drug Administration Schedule; Drug Combinations; Drug Interactions; Female; Glycopyrrolate; Humans; Indans; Lung; Male; Muscarinic Antagonists; Nebulizers and Vaporizers; Pregnancy; Pulmonary Disease, Chronic Obstructive; Quinolones; Risk Factors; Treatment Outcome | 2016 |
Population pharmacokinetics of IND/GLY (indacaterol/glycopyrronium) in COPD patients.
Topics: Adult; Aged; Aged, 80 and over; Bronchodilator Agents; Drug Combinations; Female; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Models, Biological; Pulmonary Disease, Chronic Obstructive; Quinolones | 2016 |
[Narrowing indications for inhaled steroids in COPD].
Topics: Bronchodilator Agents; Clinical Trials as Topic; Disease Progression; Drug Combinations; Glycopyrrolate; Humans; Indans; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinolones | 2016 |
[UBC internal medicine returns to the respiratory tract area].
Topics: Bronchodilator Agents; Drug Combinations; Glycopyrrolate; Humans; Indans; Nebulizers and Vaporizers; Pulmonary Disease, Chronic Obstructive; Quinolones | 2016 |
Another Choice for Prevention of COPD Exacerbations.
Topics: Adrenergic beta-2 Receptor Agonists; Female; Fluticasone-Salmeterol Drug Combination; Glucocorticoids; Glycopyrrolate; Humans; Indans; Male; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones | 2016 |
A case report of QT prolongation with glycopyrronium bromide in a patient with chronic tamoxifen use.
Topics: Administration, Inhalation; Aged; Electrocardiography; Female; Glycopyrrolate; Humans; Long QT Syndrome; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Selective Estrogen Receptor Modulators; Syncope; Tamoxifen | 2016 |
Cost Effectiveness of the Long-Acting β2-Adrenergic Agonist (LABA)/Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LABA/Inhaled Corticosteroid Combination Salmeterol/Fluticasone in Patients with Chronic Obstruct
Topics: Administration, Inhalation; Aged; Bronchodilator Agents; Canada; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Fluticasone; France; Glycopyrrolate; Health Care Costs; Humans; Indans; Italy; Male; Portugal; Pulmonary Disease, Chronic Obstructive; Quinolones; Salmeterol Xinafoate | 2016 |
Formoterol fumarate + glycopyrrolate for the treatment of chronic obstructive pulmonary disease.
Topics: Administration, Inhalation; Bronchodilator Agents; Drug Combinations; Formoterol Fumarate; Glycopyrrolate; Humans; Metered Dose Inhalers; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive | 2016 |
Indacaterol-Glycopyrronium for COPD.
Topics: Bronchodilator Agents; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Treatment Outcome | 2016 |
Indacaterol-Glycopyrronium for COPD.
Topics: Bronchodilator Agents; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Treatment Outcome | 2016 |
Indacaterol-Glycopyrronium for COPD.
Topics: Bronchodilator Agents; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Treatment Outcome | 2016 |
Indacaterol-Glycopyrronium for COPD.
Topics: Bronchodilator Agents; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Treatment Outcome | 2016 |
Glycopyrrolate/formoterol (Bevespi Aerosphere) for COPD.
Topics: Administration, Inhalation; Adrenergic beta-2 Receptor Agonists; Aerosols; Bronchodilator Agents; Drug Administration Schedule; Drug Combinations; Drug Interactions; Formoterol Fumarate; Glycopyrrolate; Humans; Lung; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Treatment Outcome | 2016 |
Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis.
Topics: Adrenergic beta-2 Receptor Agonists; Aged; Bronchodilator Agents; Clinical Trials, Phase III as Topic; Female; Fluticasone-Salmeterol Drug Combination; Forced Expiratory Volume; Glycopyrrolate; Humans; Indans; Lung; Male; Middle Aged; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Quinolones; Randomized Controlled Trials as Topic; Recovery of Function; Severity of Illness Index; Spirometry; Surveys and Questionnaires; Time Factors; Treatment Outcome; Vital Capacity | 2016 |
Combination of glycopyrronium and indacaterol inhibits carbachol-induced ERK5 signal in fibrotic processes.
Topics: Adrenergic beta-2 Receptor Antagonists; Aged; Carbachol; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glycopyrrolate; Humans; Indans; Male; Middle Aged; Mitogen-Activated Protein Kinase 7; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Pulmonary Fibrosis; Quinolones; Signal Transduction; Treatment Outcome | 2017 |
Comparative characterization of lung muscarinic receptor binding after intratracheal administration of tiotropium, ipratropium, and glycopyrrolate.
Topics: Animals; Binding Sites; Bronchodilator Agents; Glycopyrrolate; Heart; Ipratropium; Lung; Male; Muscarinic Antagonists; Pulmonary Disease, Chronic Obstructive; Rats; Rats, Sprague-Dawley; Receptors, Muscarinic; Scopolamine Derivatives; Submandibular Gland; Tiotropium Bromide; Trachea; Urinary Bladder | 2011 |